http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent 4927000 2119874000 16162000 2163193000 P12M http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember 0000933974 Q2 false http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent 2021-10-01 2021-10-01 2021-10-01 2021-10-01 P3M 0 0 http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://www.azenta.com/20230331#AccruedExpensesAndOtherCurrentLiabilities 0.3333 0.3333 0.3333 0 http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesProductsMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://www.azenta.com/20230331#LifeSciencesServicesMember http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent 0000933974 azta:ShareRepurchaseProgramNovember2022Member 2023-03-31 0000933974 azta:ShareRepurchaseProgramApril2023Member us-gaap:SubsequentEventMember 2023-04-30 0000933974 azta:ShareRepurchaseProgramSeptember2015Member 2022-11-04 0000933974 azta:ShareRepurchaseProgramNovember2022Member 2022-11-04 0000933974 azta:ShareRepurchaseProgramNovember2022AcceleratedShareRepurchaseAgreementMember 2022-11-04 0000933974 azta:ShareRepurchaseProgramSeptember2015Member 2015-09-29 0000933974 azta:ShareRepurchaseProgramNovember2022AcceleratedShareRepurchaseAgreementMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0000933974 azta:ShareRepurchaseProgramApril2023Member us-gaap:SubsequentEventMember 2023-04-01 2023-04-30 0000933974 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000933974 us-gaap:CommonStockMember 2021-10-01 2022-03-31 0000933974 us-gaap:TreasuryStockCommonMember 2023-03-31 0000933974 us-gaap:RetainedEarningsMember 2023-03-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000933974 us-gaap:TreasuryStockCommonMember 2022-12-31 0000933974 us-gaap:RetainedEarningsMember 2022-12-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000933974 us-gaap:TreasuryStockCommonMember 2022-09-30 0000933974 us-gaap:RetainedEarningsMember 2022-09-30 0000933974 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000933974 us-gaap:TreasuryStockCommonMember 2022-03-31 0000933974 us-gaap:RetainedEarningsMember 2022-03-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000933974 us-gaap:TreasuryStockCommonMember 2021-12-31 0000933974 us-gaap:RetainedEarningsMember 2021-12-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000933974 us-gaap:TreasuryStockCommonMember 2021-09-30 0000933974 us-gaap:RetainedEarningsMember 2021-09-30 0000933974 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000933974 azta:RestrictedStockPerformanceBasedSharesMember 2022-10-01 2023-03-31 0000933974 azta:RestrictedStockTimeBasedSharesMember 2021-10-01 2022-03-31 0000933974 azta:RestrictedStockPerformanceBasedSharesMember 2021-10-01 2022-03-31 0000933974 azta:BoardOfDirectorUnitsMember 2021-10-01 2022-03-31 0000933974 azta:RestrictedStockTimeBasedSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-10-01 2023-03-31 0000933974 azta:RestrictedStockTimeBasedSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2022-10-01 2023-03-31 0000933974 azta:RestrictedStockTimeBasedSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-10-01 2023-03-31 0000933974 azta:RestrictedStockTimeBasedSharesMember 2022-10-01 2023-03-31 0000933974 2024-04-01 2023-03-31 0000933974 2023-04-01 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000933974 srt:NorthAmericaMember 2023-01-01 2023-03-31 0000933974 srt:AfricaMember 2023-01-01 2023-03-31 0000933974 country:GB 2023-01-01 2023-03-31 0000933974 country:CN 2023-01-01 2023-03-31 0000933974 azta:SampleRepositorySolutionsMember 2023-01-01 2023-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2023-01-01 2023-03-31 0000933974 azta:GenomicServicesMember 2023-01-01 2023-03-31 0000933974 azta:EuropeExcludingUnitedKingdomMember 2023-01-01 2023-03-31 0000933974 azta:BMedicalMember 2023-01-01 2023-03-31 0000933974 azta:AsiaPacificOtherThanChinaMember 2023-01-01 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember 2022-10-01 2023-03-31 0000933974 srt:NorthAmericaMember 2022-10-01 2023-03-31 0000933974 srt:AfricaMember 2022-10-01 2023-03-31 0000933974 country:GB 2022-10-01 2023-03-31 0000933974 country:CN 2022-10-01 2023-03-31 0000933974 azta:SampleRepositorySolutionsMember 2022-10-01 2023-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2022-10-01 2023-03-31 0000933974 azta:GenomicServicesMember 2022-10-01 2023-03-31 0000933974 azta:EuropeExcludingUnitedKingdomMember 2022-10-01 2023-03-31 0000933974 azta:BMedicalMember 2022-10-01 2023-03-31 0000933974 azta:AsiaPacificOtherThanChinaMember 2022-10-01 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000933974 srt:NorthAmericaMember 2022-01-01 2022-03-31 0000933974 srt:AfricaMember 2022-01-01 2022-03-31 0000933974 country:GB 2022-01-01 2022-03-31 0000933974 country:CN 2022-01-01 2022-03-31 0000933974 azta:SampleRepositorySolutionsMember 2022-01-01 2022-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2022-01-01 2022-03-31 0000933974 azta:GenomicServicesMember 2022-01-01 2022-03-31 0000933974 azta:EuropeExcludingUnitedKingdomMember 2022-01-01 2022-03-31 0000933974 azta:AsiaPacificOtherThanChinaMember 2022-01-01 2022-03-31 0000933974 us-gaap:OperatingSegmentsMember 2021-10-01 2022-03-31 0000933974 srt:NorthAmericaMember 2021-10-01 2022-03-31 0000933974 srt:AfricaMember 2021-10-01 2022-03-31 0000933974 country:GB 2021-10-01 2022-03-31 0000933974 country:CN 2021-10-01 2022-03-31 0000933974 azta:SampleRepositorySolutionsMember 2021-10-01 2022-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2021-10-01 2022-03-31 0000933974 azta:GenomicServicesMember 2021-10-01 2022-03-31 0000933974 azta:EuropeExcludingUnitedKingdomMember 2021-10-01 2022-03-31 0000933974 azta:AsiaPacificOtherThanChinaMember 2021-10-01 2022-03-31 0000933974 azta:SampleRepositorySolutionsMember 2023-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2023-03-31 0000933974 azta:GenomicServicesMember 2023-03-31 0000933974 azta:BMedicalMember 2023-03-31 0000933974 azta:SampleRepositorySolutionsMember 2022-03-31 0000933974 azta:LifeSciencesProductsExcludingBMedicalMember 2022-03-31 0000933974 azta:GenomicServicesMember 2022-03-31 0000933974 azta:BMedicalMember 2022-03-31 0000933974 2021-12-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2022-02-01 2022-02-01 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-09-30 0000933974 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000933974 us-gaap:CorporateNonSegmentMember 2022-10-01 2023-03-31 0000933974 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000933974 us-gaap:CorporateNonSegmentMember 2021-10-01 2022-03-31 0000933974 azta:NonCancellableContractsAndPurchaseOrdersForInventoryMember 2023-03-31 0000933974 azta:NonCancelableInformationTechnologyRelatedCommitmentsMember 2023-03-31 0000933974 azta:NonCancelableCommitmentsMember 2023-03-31 0000933974 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-03-31 0000933974 azta:LifeSciencesServicesMember 2023-01-01 2023-03-31 0000933974 azta:LifeSciencesProductsMember 2023-01-01 2023-03-31 0000933974 us-gaap:MaterialReconcilingItemsMember 2022-10-01 2023-03-31 0000933974 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-03-31 0000933974 azta:LifeSciencesServicesMember 2022-01-01 2022-03-31 0000933974 azta:LifeSciencesProductsMember 2022-01-01 2022-03-31 0000933974 us-gaap:MaterialReconcilingItemsMember 2021-10-01 2022-03-31 0000933974 azta:LifeSciencesServicesMember 2021-10-01 2022-03-31 0000933974 azta:LifeSciencesProductsMember 2021-10-01 2022-03-31 0000933974 us-gaap:EarliestTaxYearMember 2022-10-01 2023-03-31 0000933974 srt:MinimumMember azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-10-03 0000933974 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000933974 us-gaap:RetainedEarningsMember 2022-10-01 2023-03-31 0000933974 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000933974 azta:EdwardsVacuumLlcIndemnificationDefinitiveAgreementThirdPartyWarrantyClaimMember 2023-01-01 2023-01-31 0000933974 azta:TariffsMember 2022-04-01 2022-06-30 0000933974 azta:EdwardsVacuumLlcIndemnificationDefinitiveAgreementThirdPartyWarrantyClaimMember 2023-03-31 0000933974 azta:TariffsMember 2021-03-31 0000933974 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000933974 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-10-01 2023-03-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorCryogenicsBusinessMember 2023-01-01 2023-03-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2023-01-01 2023-03-31 0000933974 azta:LifeSciencesServicesMember 2022-10-01 2023-03-31 0000933974 azta:LifeSciencesProductsMember 2022-10-01 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember azta:LifeSciencesProductsMember 2022-10-03 0000933974 azta:LifeSciencesServicesMember 2022-09-30 0000933974 azta:LifeSciencesProductsMember 2022-09-30 0000933974 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-02-01 2023-02-01 0000933974 us-gaap:TrademarksAndTradeNamesMember 2023-03-31 0000933974 us-gaap:PatentsMember 2023-03-31 0000933974 us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000933974 us-gaap:NoncompeteAgreementsMember 2023-03-31 0000933974 us-gaap:DevelopedTechnologyRightsMember 2023-03-31 0000933974 us-gaap:CustomerRelationshipsMember 2023-03-31 0000933974 us-gaap:TrademarksAndTradeNamesMember 2022-09-30 0000933974 us-gaap:PatentsMember 2022-09-30 0000933974 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0000933974 us-gaap:NoncompeteAgreementsMember 2022-09-30 0000933974 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0000933974 us-gaap:CustomerRelationshipsMember 2022-09-30 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0000933974 us-gaap:RetainedEarningsMember 2021-10-01 2022-03-31 0000933974 us-gaap:ServiceMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2022-01-01 2022-03-31 0000933974 us-gaap:ProductMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2022-01-01 2022-03-31 0000933974 us-gaap:ServiceMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2021-10-01 2022-03-31 0000933974 us-gaap:ProductMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2021-10-01 2022-03-31 0000933974 srt:WeightedAverageMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-02-01 0000933974 srt:WeightedAverageMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-02-01 0000933974 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000933974 us-gaap:ProductMember 2023-01-01 2023-03-31 0000933974 us-gaap:ServiceMember 2022-10-01 2023-03-31 0000933974 us-gaap:ProductMember 2022-10-01 2023-03-31 0000933974 us-gaap:ServiceMember 2022-01-01 2022-03-31 0000933974 us-gaap:ProductMember 2022-01-01 2022-03-31 0000933974 us-gaap:ServiceMember 2021-10-01 2022-03-31 0000933974 us-gaap:ProductMember 2021-10-01 2022-03-31 0000933974 country:US us-gaap:RevenueFromContractWithCustomerMember azta:GeographicConcentrationRiskNorthAmericaMember 2023-01-01 2023-03-31 0000933974 azta:TopIndividualCustomerMember srt:MinimumMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2023-03-31 0000933974 country:US us-gaap:RevenueFromContractWithCustomerMember azta:GeographicConcentrationRiskNorthAmericaMember 2022-10-01 2023-03-31 0000933974 country:US us-gaap:RevenueFromContractWithCustomerMember azta:GeographicConcentrationRiskNorthAmericaMember 2022-01-01 2022-03-31 0000933974 azta:TopIndividualCustomerMember srt:MinimumMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-03-31 0000933974 country:US us-gaap:RevenueFromContractWithCustomerMember azta:GeographicConcentrationRiskNorthAmericaMember 2021-10-01 2022-03-31 0000933974 us-gaap:CommonStockMember 2023-03-31 0000933974 us-gaap:CommonStockMember 2022-12-31 0000933974 us-gaap:CommonStockMember 2022-09-30 0000933974 us-gaap:CommonStockMember 2022-03-31 0000933974 us-gaap:CommonStockMember 2021-12-31 0000933974 us-gaap:CommonStockMember 2021-09-30 0000933974 us-gaap:AccountingStandardsUpdate202110Member 2023-03-31 0000933974 us-gaap:AccountingStandardsUpdate202108Member 2023-03-31 0000933974 us-gaap:AccountingStandardsUpdate202010Member 2023-03-31 0000933974 us-gaap:AccountingStandardsUpdate202006Member 2023-03-31 0000933974 us-gaap:AccountingStandardsUpdate201912Member 2023-03-31 0000933974 us-gaap:AccountingStandardsUpdate201814Member 2023-03-31 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:SoftwareDevelopmentMember 2023-03-31 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:TrademarksMember 2023-02-03 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2023-02-03 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2023-02-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:TrademarksMember 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:OrderOrProductionBacklogMember 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2022-10-03 0000933974 azta:BarkeyHoldingGmbhAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2022-07-01 0000933974 azta:BarkeyHoldingGmbhAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2022-07-01 0000933974 srt:RestatementAdjustmentMember azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2023-03-31 0000933974 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-12-31 0000933974 2022-12-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-10-03 2023-03-31 0000933974 azta:ZiathLtdAndSubsidiariesMember 2023-02-03 0000933974 azta:BarkeyHoldingGmbhAndSubsidiariesMember 2022-07-01 0000933974 azta:ZiathLtdAndSubsidiariesMember 2023-02-03 2023-02-03 0000933974 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-03-31 0000933974 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000933974 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-09-30 0000933974 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000933974 us-gaap:USTreasuryAndGovernmentMember 2023-03-31 0000933974 us-gaap:CertificatesOfDepositMember 2023-03-31 0000933974 us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000933974 us-gaap:CertificatesOfDepositMember 2022-09-30 0000933974 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000933974 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000933974 us-gaap:OperatingSegmentsMember azta:LifeSciencesServicesMember 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember azta:LifeSciencesProductsMember 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember 2023-03-31 0000933974 us-gaap:OperatingSegmentsMember azta:LifeSciencesServicesMember 2022-09-30 0000933974 us-gaap:OperatingSegmentsMember azta:LifeSciencesProductsMember 2022-09-30 0000933974 us-gaap:OperatingSegmentsMember 2022-09-30 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-03-31 0000933974 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-03-31 0000933974 azta:AcquiredIntangibleAssetsMember 2023-01-01 2023-03-31 0000933974 us-gaap:DevelopedTechnologyRightsMember 2022-10-01 2023-03-31 0000933974 azta:AcquiredIntangibleAssetsMember 2022-10-01 2023-03-31 0000933974 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-03-31 0000933974 azta:AcquiredIntangibleAssetsMember 2022-01-01 2022-03-31 0000933974 us-gaap:DevelopedTechnologyRightsMember 2021-10-01 2022-03-31 0000933974 azta:AcquiredIntangibleAssetsMember 2021-10-01 2022-03-31 0000933974 2022-03-31 0000933974 2021-09-30 0000933974 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-03-31 0000933974 us-gaap:EmployeeStockMember us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000933974 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SegmentContinuingOperationsMember 2022-10-01 2023-03-31 0000933974 us-gaap:EmployeeStockMember us-gaap:SegmentContinuingOperationsMember 2022-10-01 2023-03-31 0000933974 us-gaap:EmployeeStockMember 2022-10-01 2023-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0000933974 us-gaap:EmployeeStockMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000933974 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SegmentContinuingOperationsMember 2021-10-01 2022-03-31 0000933974 us-gaap:EmployeeStockMember us-gaap:SegmentContinuingOperationsMember 2021-10-01 2022-03-31 0000933974 us-gaap:EmployeeStockMember 2021-10-01 2022-03-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-03-31 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:TrademarksMember 2023-02-03 2023-02-03 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2023-02-03 2023-02-03 0000933974 azta:ZiathLtdAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2023-02-03 2023-02-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:TrademarksMember 2022-10-03 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:OrderOrProductionBacklogMember 2022-10-03 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:DevelopedTechnologyRightsMember 2022-10-03 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember us-gaap:CustomerRelationshipsMember 2022-10-03 2022-10-03 0000933974 azta:BarkeyHoldingGmbhAndSubsidiariesMember 2022-07-01 2022-07-01 0000933974 2023-05-08 0000933974 azta:ShareRepurchaseProgramNovember2022AcceleratedShareRepurchaseAgreementMember 2022-11-28 2022-11-28 0000933974 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000933974 us-gaap:TreasuryStockCommonMember 2022-10-01 2023-03-31 0000933974 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-03-31 0000933974 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000933974 us-gaap:CommonStockMember 2022-10-01 2023-03-31 0000933974 2021-10-01 2022-09-30 0000933974 2020-10-01 2021-09-30 0000933974 azta:ThomasHLeePartnersLpMember 2022-02-01 2022-02-01 0000933974 azta:ThomasHLeePartnersLpMember 2023-03-31 0000933974 azta:ThomasHLeePartnersLpMember 2022-02-01 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2022-10-01 2023-03-31 0000933974 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2023-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000933974 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-03-31 0000933974 azta:LifeSciencesServicesMember 2023-03-31 0000933974 azta:LifeSciencesProductsMember 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-10-03 0000933974 2023-01-01 2023-03-31 0000933974 2022-01-01 2022-03-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2022-01-01 2022-03-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2021-10-01 2022-03-31 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2021-10-01 2022-09-30 0000933974 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember azta:SemiconductorAutomationBusinessMember 2022-02-01 0000933974 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-02-01 0000933974 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-02-01 0000933974 2021-10-01 2022-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-10-03 2022-10-03 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2023-01-01 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-10-01 2023-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2022-01-01 2022-03-31 0000933974 azta:BMedicalSystemsS.a.r.lAndSubsidiariesMember 2021-10-01 2022-03-31 0000933974 2022-10-01 2023-03-31 0000933974 2023-03-31 0000933974 2022-09-30 iso4217:USD iso4217:EUR xbrli:pure azta:segment azta:lease xbrli:shares iso4217:USD xbrli:shares iso4217:USD iso4217:EUR azta:country

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

​ | ​
☒ | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
​ | ​
​ | For the quarterly period ended: March 31, 2023
​ | ​
​ | OR
​ | ​
☐ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to _________

Commission File Number 000-25434

AZENTA, INC.

(Exact name of registrant as specified in its charter)

​ | ​
Delaware | 04-3040660
(State or other jurisdiction of | (I.R.S. Employer
incorporation or organization) | Identification No.)

200 Summit Drive 6th Floor

Burlington, Massachusetts

(Address of principal executive offices)

01803

(Zip Code)

Registrant’s telephone number, including area code: (978) 262-2626

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value | AZTA | The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

​ | ​ | ​ | ​
Large accelerated filer | ☒ | Accelerated filer | ☐
​ | ​ | ​ | ​
Non-accelerated filer | ☐ | Smaller reporting company | ☐
​ | ​ | ​ | ​
​ | ​ | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, May 8, 2023: common stock, $0.01 par value and 65,166,558 shares outstanding.

​

​

​

Table of Contents

AZENTA, INC.

Table of Contents

​

​ | PAGE NUMBER
​ | ​
PART I. FINANCIAL INFORMATION | ​
Item 1. Consolidated Financial Statements | ​
Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (unaudited) | 3
Consolidated Statements of Operations for the three and six months ended March 31, 2023 and 2022 (unaudited) | 4
Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended March 31, 2023 and 2022 (unaudited) | 5
Consolidated Statements of Cash Flows for the six months ended March 31, 2023 and 2022 (unaudited) | 6
Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended March 31, 2023 and 2022 (unaudited) | 8
Notes to Consolidated Financial Statements (unaudited) | 10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 40
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 55
Item 4. Controls and Procedures | 56
PART II. OTHER INFORMATION | ​
Item 1. Legal Proceedings | 57
Item 1A. Risk Factors | 57
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 57
Item 6. Exhibits | 58
Signatures | 59

​

​

​

2

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

AZENTA, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30,
​ | ​ | 2023 | ​ | 2022
Assets |  | ​ |  |  | ​ |
Current assets |  | ​ |  |  | ​ |
Cash and cash equivalents | ​ | $ | 667,365 | ​ | $ | 658,274
Short-term marketable securities | ​ |  | 513,651 | ​ |  | 911,764
Accounts receivable, net of allowance for expected credit losses ($7,696 and $5,162, respectively) | ​ |  | 167,960 | ​ |  | 163,758
Inventories | ​ |  | 150,727 | ​ |  | 85,544
Derivative asset | ​ | ​ | 1,278 | ​ | ​ | 124,789
Short-term restricted cash | ​ | ​ | 4,021 | ​ | ​ | 382,596
Prepaid expenses and other current assets | ​ |  | 80,732 | ​ |  | 132,621
Total current assets | ​ |  | 1,585,734 | ​ |  | 2,459,346
Property, plant and equipment, net | ​ |  | 215,301 | ​ |  | 154,470
Long-term marketable securities | ​ |  | 266,176 | ​ |  | 352,020
Long-term deferred tax assets | ​ |  | 490 | ​ |  | 1,169
Goodwill | ​ |  | 790,494 | ​ |  | 513,623
Intangible assets, net | ​ |  | 323,927 | ​ |  | 178,401
Other assets | ​ |  | 67,692 | ​ |  | 57,093
Total assets | ​ | $ | 3,249,814 | ​ | $ | 3,716,122
Liabilities and stockholders' equity | ​ |  | ​ | ​ |  |
Current liabilities | ​ |  | ​ | ​ |  |
Accounts payable | ​ | $ | 45,306 | ​ | $ | 38,654
Deferred revenue | ​ |  | 46,048 | ​ |  | 39,748
Accrued warranty and retrofit costs | ​ |  | 5,380 | ​ |  | 2,890
Accrued compensation and benefits | ​ |  | 27,632 | ​ |  | 41,898
Accrued income taxes payable | ​ |  | 5,228 | ​ |  | 28,419
Accrued expenses and other current liabilities | ​ |  | 83,050 | ​ |  | 78,937
Total current liabilities | ​ |  | 212,644 | ​ |  | 230,546
Long-term tax reserves | ​ |  | 1,720 | ​ |  | 1,684
Long-term deferred tax liabilities | ​ |  | 70,104 | ​ |  | 64,555
Long-term pension liabilities | ​ |  | 280 | ​ |  | 261
Long-term operating lease liabilities | ​ | ​ | 57,137 | ​ | ​ | 49,227
Other long-term liabilities | ​ |  | 12,702 | ​ |  | 6,463
Total liabilities | ​ |  | 354,587 | ​ |  | 352,736
​ | ​ |  |  | ​ |  |
Stockholders' equity | ​ |  |  | ​ |  |
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding | ​ |  | — | ​ |  | —
Common stock, $0.01 par value - 125,000,000 shares authorized, 82,602,702 shares issued and 69,147,387 shares outstanding at March 31, 2023, 88,482,125 shares issued and 75,020,256 shares outstanding at September 30, 2022 | ​ |  | 826 | ​ |  | 885
Additional paid-in capital | ​ |  | 1,495,118 | ​ |  | 1,992,017
Accumulated other comprehensive loss | ​ |  | (38,870) | ​ |  | (83,916)
Treasury stock, at cost - 13,461,869 shares at March 31, 2023 and September 30, 2022 | ​ |  | (200,956) | ​ |  | (200,956)
Retained earnings | ​ |  | 1,639,109 | ​ |  | 1,655,356
Total stockholders' equity | ​ | ​ | 2,895,227 | ​ | ​ | 3,363,386
Total liabilities and stockholders' equity | ​ | $ | 3,249,814 | ​ | $ | 3,716,122

​

The accompanying notes are an integral part of these unaudited consolidated financial statements.

​

3

Table of Contents

AZENTA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share data)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended | ​
​ | ​ | March 31, | ​ | March 31, | ​
​ |  | 2023 |  | 2022 |  | 2023 |  | 2022 |
Revenue |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Products | ​ | $ | 51,917 | ​ | $ | 49,449 | ​ | $ | 137,715 | ​ | $ | 95,318 | ​
Services | ​ |  | 96,484 | ​ |  | 96,095 | ​ |  | 189,052 | ​ | ​ | 189,878 | ​
Total revenue | ​ |  | 148,401 | ​ |  | 145,544 | ​ |  | 326,767 | ​ |  | 285,196 | ​
Cost of revenue | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Products | ​ |  | 40,009 | ​ |  | 24,953 | ​ |  | 94,108 | ​ |  | 49,475 | ​
Services | ​ |  | 55,156 | ​ |  | 49,766 | ​ |  | 105,558 | ​ |  | 97,852 | ​
Total cost of revenue | ​ |  | 95,165 | ​ |  | 74,719 | ​ |  | 199,666 | ​ |  | 147,327 | ​
Gross profit | ​ |  | 53,236 | ​ |  | 70,825 | ​ |  | 127,101 | ​ |  | 137,869 | ​
Operating expenses | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Research and development | ​ |  | 8,520 | ​ |  | 6,896 | ​ |  | 16,056 | ​ |  | 13,381 | ​
Selling, general and administrative | ​ | ​ | 73,339 | ​ |  | 67,915 | ​ |  | 165,891 | ​ |  | 128,626 | ​
Contingent consideration - fair value adjustments | ​ |  | (17,145) | ​ | ​ | 600 | ​ | ​ | (17,145) | ​ | ​ | 600 | ​
Restructuring charges | ​ |  | 1,499 | ​ |  | 122 | ​ |  | 2,961 | ​ |  | 295 | ​
Total operating expenses | ​ |  | 66,213 | ​ |  | 75,533 | ​ |  | 167,763 | ​ |  | 142,902 | ​
Operating loss | ​ |  | (12,977) | ​ |  | (4,708) | ​ |  | (40,662) | ​ |  | (5,033) | ​
Interest income | ​ |  | 10,394 | ​ |  | 3,076 | ​ |  | 21,059 | ​ |  | 3,111 | ​
Interest expense | ​ |  | — | ​ |  | (1,555) | ​ |  | — | ​ |  | (2,010) | ​
Loss on extinguishment of debt | ​ |  | — | ​ |  | (632) | ​ |  | — | ​ |  | (632) | ​
Other income (expense) | ​ |  | (2,668) | ​ |  | (1,170) | ​ |  | (1,523) | ​ |  | (2,248) | ​
Loss before income taxes | ​ |  | (5,251) | ​ |  | (4,989) | ​ |  | (21,126) | ​ |  | (6,812) | ​
Income tax benefit | ​ |  | (3,260) | ​ |  | (3,173) | ​ |  | (7,900) | ​ |  | (7,853) | ​
Income (loss) from continuing operations | ​ |  | (1,991) | ​ |  | (1,816) | ​ |  | (13,226) | ​ |  | 1,041 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (2,936) | ​ |  | 2,121,690 | ​ |  | (2,936) | ​ |  | 2,162,152 | ​
Net income (loss) | ​ | $ | (4,927) | ​ | $ | 2,119,874 | ​ | $ | (16,162) | ​ | $ | 2,163,193 | ​
Basic net income (loss) per share: | ​ | ​ |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Income (loss) from continuing operations | ​ | $ | (0.03) | ​ | $ | (0.02) | ​ | $ | (0.19) | ​ | $ | 0.01 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (0.04) | ​ |  | 28.31 | ​ |  | (0.04) | ​ |  | 28.90 | ​
Basic net income (loss) per share | ​ | $ | (0.07) | ​ | $ | 28.28 | ​ | $ | (0.23) | ​ | $ | 28.91 | ​
Diluted net income (loss) per share: | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Income (loss) from continuing operations | ​ | $ | (0.03) | ​ | $ | (0.02) | ​ | $ | (0.19) | ​ | $ | 0.01 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (0.04) | ​ |  | 28.31 | ​ |  | (0.04) | ​ | ​ | 28.77 | ​
Diluted net income (loss) per share | ​ | $ | (0.07) | ​ | $ | 28.28 | ​ | $ | (0.23) | ​ | $ | 28.79 | ​
Weighted average shares used in computing net income (loss) per share: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Basic | ​ |  | 69,111 | ​ |  | 74,958 | ​ |  | 70,858 | ​ |  | 74,823 | ​
Diluted | ​ |  | 69,111 | ​ |  | 74,958 | ​ |  | 70,858 | ​ |  | 75,145 | ​

​

The accompanying notes are an integral part of these unaudited consolidated financial statements.

​

​

4

Table of Contents

AZENTA, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited)

(In thousands)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended | ​
​ | ​ | March 31, | ​ | March 31, | ​
​ |  | 2023 |  | 2022 |  | 2023 |  | 2022 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss) | ​ | $ | (4,927) | ​ | $ | 2,119,874 | ​ | $ | (16,162) | ​ | $ | 2,163,193 | ​
Other comprehensive income (loss), net of tax: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Foreign currency translation reclassification adjustments included in income from discontinued operations (Note 2) | ​ | ​ | — | ​ | ​ | (16,567) | ​ | ​ | — | ​ | ​ | (16,567) | ​
Net investment hedge currency translation adjustment, net of tax effects of ($4,531) and ($24,239) for the three and six months ended March 31, 2023 and net of tax effects of $3,524 for the three and six months ended March 31, 2022. | ​ | ​ | (13,133) | ​ | ​ | 7,149 | ​ | ​ | (70,260) | ​ | ​ | 7,149 | ​
Foreign currency translation adjustments | ​ |  | 33,850 | ​ |  | (18,907) | ​ |  | 111,264 | ​ |  | (14,980) | ​
Changes in unrealized gain on marketable securities, net of tax effects of $858 and $1,395 for the three and six months ended March 31, 2023 and net of tax effects of ($874) and ($874) for the three months and six months ended March 31, 2022. | ​ |  | 2,487 | ​ |  | (3,306) | ​ |  | 4,042 | ​ |  | (2,432) | ​
Actuarial gains, net of tax effects of $0 and $0 during the three and six months ended March 31, 2023, $0 and $0 during the three and six months ended March 31, 2022 | ​ |  | — | ​ |  | 84 | ​ |  | — | ​ |  | 81 | ​
Total other comprehensive income (loss), net of tax | ​ |  | 23,204 | ​ |  | (31,547) | ​ |  | 45,046 | ​ |  | (26,749) | ​
Comprehensive income (loss) | ​ | $ | 18,277 | ​ | $ | 2,088,327 | ​ | $ | 28,884 | ​ | $ | 2,136,444 | ​

​

The accompanying notes are an integral part of these unaudited consolidated financial statements.

​

​

5

Table of Contents

AZENTA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Months Ended | ​ |
​ | ​ | March 31, | ​ | ​
​ |  | 2023 |  | 2022 |  |
Cash flows from operating activities |  | ​ |  | ​ | ​ |  |  | ​
Net income (loss) | ​ | $ | (16,162) | ​ | $ | 2,163,193 | ​ | ​
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ​ |  | ​ | ​ |  | ​ | ​ | ​
Depreciation and amortization | ​ | ​ | 42,140 | ​ | ​ | 26,005 | ​ | ​
Stock-based compensation | ​ |  | 6,096 | ​ |  | 7,230 | ​ | ​
Contingent consideration adjustment | ​ | ​ | (17,145) | ​ | ​ | 600 | ​ | ​
Amortization of deferred financing costs | ​ |  | — | ​ |  | 66 | ​ | ​
Amortization of premium on marketable securities and deferred financing costs | ​ |  | (5,284) | ​ |  | — | ​ | ​
Deferred income taxes | ​ |  | (20,843) | ​ |  | 11,054 | ​ | ​
Loss on extinguishment of debt | ​ |  | — | ​ |  | 632 | ​ | ​
Purchase accounting impact on inventory | ​ |  | 5,781 | ​ |  | — | ​ | ​
(Gain) loss on disposals of property, plant and equipment | ​ |  | 31 | ​ |  | (30) | ​ | ​
Gain on divestiture, net of tax | ​ | ​ | — | ​ | ​ | (2,130,351) | ​ | ​
Fees paid stemming from divestiture | ​ | ​ | — | ​ | ​ | (52,461) | ​ | ​
Accounts receivable | ​ |  | 23,925 | ​ |  | (456) | ​ | ​
Inventories | ​ |  | (11,504) | ​ |  | (55,033) | ​ | ​
Accounts payable | ​ |  | (5,677) | ​ |  | (7,906) | ​ | ​
Deferred revenue | ​ |  | 3,625 | ​ |  | 5,215 | ​ | ​
Accrued warranty and retrofit costs | ​ |  | 622 | ​ |  | (198) | ​ | ​
Accrued compensation and tax withholdings | ​ |  | (21,797) | ​ |  | 10,875 | ​ | ​
Accrued restructuring costs | ​ |  | 820 | ​ |  | (113) | ​ | ​
Other current assets and liabilities | ​ | ​ | (23,798) | ​ |  | (34,061) | ​ | ​
Net cash used in operating activities | ​ |  | (39,170) | ​ |  | (55,739) | ​ | ​
Cash flows from investing activities | ​ | ​ |  | ​ |  |  | ​ | ​
Purchases of property, plant and equipment | ​ |  | (21,705) | ​ |  | (44,326) | ​ | ​
Purchases of technology intangibles | ​ | ​ | — | ​ | ​ | (4,000) | ​ | ​
Purchases of marketable securities | ​ |  | (233,584) | ​ |  | (1,074,428) | ​ | ​
Sales and maturities of marketable securities | ​ | ​ | 728,171 | ​ | ​ | 3,710 | ​ | ​
Proceeds from divestiture, net of cash transferred | ​ | ​ | — | ​ |  | 2,927,245 | ​ | ​
Net Investment hedge settlement | ​ | ​ | 29,313 | ​ | ​ | — | ​ | ​
Acquisitions, net of cash acquired | ​ |  | (387,665) | ​ |  | — | ​ | ​
Net cash provided by investing activities | ​ |  | 114,530 | ​ |  | 1,808,201 | ​ | ​
Cash flows from financing activities | ​ |  |  | ​ |  |  | ​ | ​
Proceeds from issuance of common stock | ​ |  | — | ​ |  | 3,461 | ​ | ​
Payments of financing costs | ​ |  | — | ​ |  | (312) | ​ | ​
Principal payments on debt | ​ |  | — | ​ |  | (49,725) | ​ | ​
Common stock dividends paid | ​ | ​ | — | ​ | ​ | (7,494) | ​ | ​
Payment for contingent consideration related to acquisition | ​ | ​ | — | ​ | ​ | (9,400) | ​ | ​
Payment of finance leases | ​ | ​ | (230) | ​ | ​ | — | ​ | ​
Stock repurchase | ​ | ​ | (500,000) | ​ | ​ | — | ​ | ​
Withholding tax payments on net share settlements on equity awards | ​ |  | (4,906) | ​ |  | — | ​ | ​
Net cash used in financing activities | ​ |  | (505,136) | ​ |  | (63,470) | ​ | ​
Effects of exchange rate changes on cash and cash equivalents | ​ |  | 60,355 | ​ |  | (25,372) | ​ | ​
Net decrease in cash, cash equivalents and restricted cash | ​ |  | (369,421) | ​ |  | 1,663,620 | ​ | ​
Cash, cash equivalents and restricted cash, beginning of period |  |  | 1,041,296 |  |  | 285,333 |  |
Cash, cash equivalents and restricted cash, end of period | ​ | $ | 671,875 |  | $ | 1,948,953 | ​ |
Supplemental disclosures: | ​ |  |  | ​ |  |  | ​ | ​
Cash paid for income taxes, net | ​ |  | 35,286 | ​ | ​ | 20,782 | ​ | ​
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | March 31, | ​ | ​ | September 30, | ​ | ​
​ | ​ | ​ | 2023 | ​ | ​ | 2022 | ​ | ​
Cash and cash equivalents of continuing operations | ​ | $ | 667,365 | ​ | $ | 658,274 | ​ | ​
Short-term restricted cash | ​ | ​ | 4,021 | ​ | ​ | 382,596 | ​ | ​
Long-term restricted cash included in other assets | ​ | ​ | 489 | ​ | ​ | 426 | ​ | ​
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows | ​ | $ | 671,875 | ​ | $ | 1,041,296 | ​ | ​

​

The accompanying notes are an integral part of these unaudited consolidated financial statements.

​

6

Table of Contents

​

​

7

Table of Contents

AZENTA, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(unaudited)

(In thousands, except share data)

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Common | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common | ​ | Stock at | ​ | Additional | ​ | Other | ​ | Retained Earnings | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Stock | ​ | Par | ​ | Paid-In | ​ | Comprehensive | ​ | (Accumulated | ​ | Treasury | ​ | Total
​ | ​ | Shares | ​ | Value | ​ | Capital | ​ | Income (Loss) | ​ | Deficit) | ​ | Stock | ​ | Equity
​ | ​ | (In thousands, except share data)
Balance December 31, 2022 |  | 82,515,917 |  | $ | 824 |  | $ | 1,489,554 |  | $ | (62,074) |  | $ | 1,644,041 |  | $ | (200,956) |  | $ | 2,871,389
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | ​ | 86,785 | ​ | ​ | — | ​ | ​ | 1,573 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,573
Retirement of treasury shares | ​ | ​ | ​ | ​ | 2 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 3,991 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,991
Net investment hedge currency translation adjustment, net of tax effect of ($4,531) | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (13,133) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (13,133)
Foreign currency translation adjustments | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 33,850 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 33,850
Changes in unrealized gains on marketable securities, net of tax effect of $858 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,487 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,487
Net income (loss) | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (4,927) | ​ | ​ | — | ​ | ​ | (4,927)
Other | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (5) | ​ | ​ | — | ​ | ​ | (5)
Balance March 31, 2023 | ​ | 82,602,702 | ​ | $ | 826 | ​ | $ | 1,495,118 | ​ | $ | (38,870) | ​ | $ | 1,639,109 | ​ | $ | (200,956) | ​ | $ | 2,895,227
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance December 31, 2021 | ​ | 88,375,410 | ​ | $ | 884 | ​ | $ | 1,977,571 | ​ | $ | 24,149 | ​ | $ | (434,225) | ​ | $ | (200,956) | ​ | $ | 1,367,423
Shares issued under restricted stock and purchase plans, net | ​ | 74,673 | ​ | ​ | 1 | ​ | ​ | 3,460 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,461
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 5,765 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,765
Net investment hedge currency translation adjustment, net of tax effect of $3,524 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,149 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,149
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (16,567) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (16,567)
Foreign currency translation adjustments | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (18,907) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (18,907)
Changes in unrealized gains on marketable securities, net of tax effects of ($874) | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ | (3,306) | ​ | ​ |  | ​ | ​ |  | ​ | ​ | (3,306)
Actuarial losses, net of tax effects of $0 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 84 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 84
Net income | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,119,874 | ​ | ​ | — | ​ | ​ | 2,119,874
Balance March 31, 2022 | ​ | 88,450,083 | ​ | $ | 885 | ​ | $ | 1,986,796 | ​ | $ | (7,398) | ​ | $ | 1,685,649 | ​ | $ | (200,956) | ​ | $ | 3,464,976
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance September 30, 2022 | ​ | 88,482,125 | ​ | $ | 885 | ​ | $ | 1,992,017 | ​ | $ | (83,916) | ​ | $ | 1,655,356 | ​ | $ | (200,956) | ​ | $ | 3,363,386
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes | ​ | 210,711 | ​ | ​ | — | ​ | ​ | 1,573 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (4,629) | ​ | ​ | (3,056)
Accelerated share repurchase | ​ | (6,090,134) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (500,000) | ​ | ​ | (500,000)
Retirement of treasury shares | ​ | — | ​ | ​ | (59) | ​ | ​ | (504,568) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 504,629 | ​ | ​ | 2
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 6,096 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,096
Net income (loss) | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (16,162) | ​ | ​ | — | ​ | ​ | (16,162)
Net investment hedge currency translation adjustment, net of tax effect of ($24,239) | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (70,260) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (70,260)
Foreign currency translation adjustments | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 111,264 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 111,264
Changes in unrealized losses on marketable securities, net of tax effect of $1,395 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,042 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,042
Other | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (85) | ​ | ​ | — | ​ | ​ | (85)
Balance March 31, 2023 | ​ | 82,602,702 | ​ | $ | 826 | ​ | $ | 1,495,118 | ​ | $ | (38,870) | ​ | $ | 1,639,109 | ​ | $ | (200,956) | ​ | $ | 2,895,227
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance September 30, 2021 | ​ | 87,808,922 | ​ | $ | 878 | ​ | $ | 1,976,112 | ​ | $ | 19,351 | ​ | $ | (470,051) | ​ | $ | (200,956) | ​ | $ | 1,325,334
Shares issued under restricted stock and purchase plans, net | ​ | 641,161 | ​ | ​ | 7 | ​ | ​ | 3,455 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,462
Stock-based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 7,229 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,229
Common stock dividends declared, at $0.10 per share | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (7,493) | ​ | ​ | — | ​ | ​ | (7,493)
Net investment hedge currency translation adjustment, net of tax effect of $3,524 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,149 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,149
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (16,567) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (16,567)
Foreign currency translation adjustments | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (14,980) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (14,980)
Changes in unrealized losses on marketable securities, net of tax effects of ($874) | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,432) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,432)
Actuarial losses, net of tax effects of $0 | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 81 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 81
Net income | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,163,193 | ​ | ​ | — | ​ | ​ | 2,163,193
Balance March 31, 2022 | ​ | 88,450,083 | ​ | $ | 885 | ​ | $ | 1,986,796 | ​ | $ | (7,398) | ​ | $ | 1,685,649 | ​ | $ | (200,956) | ​ | $ | 3,464,976

​

The accompanying notes are an integral part of these unaudited consolidated financial statements.

8

Table of Contents

​

​

​

9

Table of Contents

AZENTA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

​

​

1. Nature of Operation

Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of life sciences sample exploration and management solutions for the life sciences market. The Company supports its customers from research to clinical development with its sample management, automated storage, and genomic services expertise to help bring impactful therapies to market faster.

Risks and Uncertainties

The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, risk of disruption in its supply chain, the implementation of tariffs and export controls, inflation, dependence on key personnel, protection of proprietary technology, and compliance with domestic and foreign regulatory authorities and agencies.

The COVID-19 pandemic has had varying impacts on our financial results. In the first two years of the pandemic, any marginal adverse impact was more than offset by incremental orders related to virus research, COVID testing and vaccine development and commercialization in 2021 and through the first half of 2022. There has been limited COVID-related demand after the second fiscal quarter of 2022, and therefore, our revenue trends since then have been negatively impacted when compared to prior periods. Future impacts on the Company’s financial results are not fully determinable, as the continuing impact of the pandemic on the economy and markets which the Company serves is as yet unknown, but will be dependent, in part, on future variants of the virus and vaccine effectiveness against these variants and new or prolonged government responses to the pandemic. The Company’s financial results will also depend on variables including reduced demand from its customers, the degree that the supply chain may be constrained which could impact its delivery of products and services and the potential negative impact on its operations if there is an outbreak among the Company’s employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats.

​

​

2. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation

The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation.

In the opinion of the Company, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, and its results of operations for the three months and six months ended March 31, 2023 and 2022, and cash flows for the six months ended March 31, 2023 and 2022, respectively. The consolidated balance sheet at September 30, 2022 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements

Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission for the fiscal year ended September 30, 2022 (the “2022 Annual Report on Form 10-K”).

10

Table of Contents

Use of Estimates

The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, contingent consideration liabilities related to business combinations, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. Actual results could differ from these estimates.

The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within the analysis of its financial statements.

​

Business Combinations

The Company accounts for business acquisitions using the purchase method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents the excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed.

​

Significant judgment is used in determining fair values of assets acquired and liabilities assumed and contingent consideration, as well as intangibles and their estimated useful lives. Fair value and useful life determinations may be based on, among other factors, estimates of future expected cash flows and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as our current and future operating results. Actual results may vary from these estimates that may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within our operating results.

​

Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled.

​

Foreign Currency Translation

Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses)” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $0.9 million and $1.2 million for the three months ended March 31, 2023 and 2022, respectively. Net foreign currency transaction and remeasurement losses were $0.8 million and $3.2 million during the six months ended March 31, 2023 and 2022, respectively.

The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income (loss)” in the Company’s Consolidated Balance Sheets and

11

Table of Contents

presented as “Foreign currency translation adjustments” in the Company’s Consolidated Statements of Comprehensive Income (Loss).

Derivative Financial Instruments

The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses)” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2023 and 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended | ​
​ | ​ | March 31, | ​ | March 31, | ​
​ |  | 2023 |  | 2022 |  | 2023 |  | 2022 |
Realized gains (losses) on derivatives not designated as hedging instruments | ​ | $ | (533) | ​ | $ | 1,125 | ​ | $ | (2,112) | ​ | $ | 1,054 | ​

​

The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.

Hedging Activities

On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $1.03 billion for approximately €915 million at a weighted average interest rate of approximately 1.196%. The designated notional amount is $960 million and the actual interest rate is 1.283%. The 1.283% rate was in the range of the market value for that day and is the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of our Euro denominated subsidiaries which requires an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852 million and received a notional amount of $960 million at an exchange rate of 1.1261, which includes realization of a gain of $29.3 million, which was recorded in “Accumulated other comprehensive income (loss)”.

On February 1, 2023, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $436 million for approximately €400 million at a weighted average interest rate of approximately 1.66%. The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024.

12

Table of Contents

The cross-currency swaps are marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of “Accumulated other comprehensive items, net,” on the Consolidated Statements of Comprehensive Income (Loss). Interest accrued on the cross-currency swap is recorded within “Interest income” on the Consolidated Statements of Operations. For the three and six months ended March 31, 2023, the Company recorded a net loss of $13.1 and $70.3 million, respectively to “Accumulated other comprehensive income (loss)” and recorded “Interest income” of $2.2 million and $5.3 million on these instrument for the three and six months ended March 31, 2023, respectively.

Fair Value Measurement

The Company measures certain financial assets and liabilities, including cash equivalents, available-for-sale securities, accounts receivable, accounts payable, contingent consideration liability and derivative instruments at fair value. The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”) establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Available-for-sale securities and derivative instruments are measured at fair value based on quoted market prices or observable inputs other than quoted market prices for identical or similar assets or liabilities. Contingent consideration liabilities that are recorded at fair value are based on level 3 inputs. The carrying amounts of cash equivalents, accounts receivable and accounts payable approximate their fair value due to their short-term nature.

Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns

Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in “Revenue” in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers.

Leases

The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.

The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability.

The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other

13

Table of Contents

current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets.

Recently Issued Accounting Pronouncements

In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. The ASUs provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the ASUs are only available until December 31, 2022, when the reference rate replacement activity was expected to be completed. There were no significant accounting impacts on the Company’s consolidated financial statements and related disclosures as a result of the adoption of these ASU’s. In December 2022, the FASB issued ASU 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” extending the relief offered in this series of ASUs through December 31, 2024. We have not adopted this guidance yet.

Recently Adopted Accounting Pronouncements

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in fiscal 2023.

​

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022. The impact of the adoption of this ASU is immaterial to the Company’s consolidated financial statements.

In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASCs that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU did not affect the Company's consolidated financial statements or disclosures. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022.

In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. We adopted this standard effective on October 1, 2022, the beginning of fiscal 2023 using the modified retrospective method. There was no impact to retained earnings at the date of adoption.

In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715, Compensation – Retirement Benefits to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for

14

Table of Contents

significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income or loss expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption was permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022. There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption was permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022. There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU.

Other

For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2022 Annual Report on Form 10-K.

3. Discontinued Operations

Disposition of the Semiconductor Automation Business

On September 20, 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (“THL”) and the Company determined that the semiconductor automation business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results are reflected in the Company’s financial statements as a discontinued operation, and assets and liabilities were classified as assets and liabilities held for sale. On February 1, 2022, the Company completed the sale of the semiconductor automation business for $2.9 billion in cash. As part of the transaction, the Company recorded an $18.1 million liability related to retention bonuses and cash settled stock-based awards for former employees of the Company that were conveyed with the transaction. The Company paid $0.6 million of these payments during the year ended September 30, 2022 and remitted the remaining payments to THL in November 2022, and THL directly paid the Company’s former employees. Following the completion of the sale, the Company no longer serves the semiconductor market.

In connection with the closing of the sale, the Company and THL entered into a transition services agreement, to which both the Company and THL will provide each other with certain transition services related to finance and accounting, information technology, human resources, compliance, facilities, legal and research and development support, for time periods ranging from three to 24 months. In addition, the Company entered into two separate lease agreements for leases back to the Company for portions of the facilities that previously served as its corporate headquarters in Chelmsford, Massachusetts, and were sold to THL as part of the sale agreement. Each lease provides for a term of 24 months, which may be terminated earlier by the Company upon 90 days’ notice to THL. As of March 31, 2023, one lease is still in effect. The transition services agreement and lease agreements approximate fair value and there is no material impact to the Company’s results.

The following table presents the financial results of discontinued operations with respect to the semiconductor automation business (in thousands).

​

15

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Three Months Ended March 31, | ​ | ​ | ​ | Six Months Ended March 31,
​ | ​ |  | ​ | 2022 | ​ | ​ | 2022
Revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
Products | ​ | ​ | ​ | $ | 56,722 | ​ | ​ | $ | 244,962
Services | ​ | ​ | ​ | ​ | 4,038 | ​ | ​ | ​ | 19,468
Total revenue | ​ | ​ | ​ | ​ | 60,760 | ​ | ​ | ​ | 264,430
Cost of revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Products | ​ | ​ | ​ | ​ | 33,568 | ​ | ​ | ​ | 141,165
Services | ​ | ​ | ​ | ​ | 2,850 | ​ | ​ | ​ | 11,159
Total cost of revenue | ​ | ​ | ​ | ​ | 36,418 | ​ | ​ | ​ | 152,324
Gross profit | ​ | ​ | ​ | ​ | 24,342 | ​ | ​ | ​ | 112,106
Operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ | ​ | ​ | ​ | 4,746 | ​ | ​ | ​ | 18,486
Selling, general and administrative | ​ | ​ | ​ | ​ | 7,466 | ​ | ​ | ​ | 30,142
Total operating expenses | ​ | ​ | ​ | ​ | 12,212 | ​ | ​ | ​ | 48,628
Operating income | ​ | ​ | ​ | ​ | 12,130 | ​ | ​ | ​ | 63,478
Gain on divestiture | ​ | ​ | ​ | ​ | 2,561,420 | ​ | ​ | ​ | 2,561,374
Income before income taxes | ​ | ​ | ​ | ​ | 2,573,550 | ​ | ​ | ​ | 2,624,852
Income tax provision | ​ | ​ | ​ | ​ | 451,860 | ​ | ​ | ​ | 462,700
Net income from discontinued operations | ​ | ​ | ​ | $ | 2,121,690 | ​ | ​ | $ | 2,162,152

​

During the three months ended March 31, 2023, the Company recorded a $0.4 million loss on divestiture.

The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the semiconductor automation business that are included in the Consolidated Statements of Cash Flows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Three Months Ended March 31, | ​ | ​ | Six Months Ended March 31,
​ | ​ | ​ | ​ | ​ | 2022 | ​ | ​ | ​ | 2022
Depreciation and amortization | ​ | ​ | ​ | $ | - | ​ | ​ | $ | -
Capital expenditures | ​ | ​ | ​ | $ | 579 | ​ | ​ | $ | 2,862
Stock-based compensation | ​ | ​ | ​ | $ | 3,109 | ​ | ​ | $ | 8,032

​

​

​

​

​

​

Disposition of the Semiconductor Cryogenics Business

During the three months ended March 31, 2023, the Company recorded a $2.5 million loss on divestiture of the Semiconductor Cryogenics business, due to the accrual of a liability related to a claim.

​

4. Marketable Securities

The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the accompanying unaudited Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date.

Unrealized gains and losses are excluded from earnings and reported as a separate component of “Accumulated other comprehensive income (loss)” in the accompanying unaudited Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of “Other income (expenses)” in the accompanying unaudited Consolidated Statements of Operations. The Company had sales and maturities of marketable securities of $121.0 million and $728.2 million in the three and six months ended March 31, 2023, respectively. There were insignificant

16

Table of Contents

sales and maturities of marketable securities in each of the three and six months ended March 31, 2022, respectively. There were insignificant realized gain or loss in each of the three and six months ended March 31, 2023 and 2022.

The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized gains (losses) on the short-term and long-term marketable securities as of March 31, 2023 and September 30, 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Gross |  | Gross |  | ​
​ | ​ | Amortized | ​ | Unrealized | ​ | Unrealized | ​ | ​
​ | ​ | Cost | ​ | Losses | ​ | Gains | ​ | Fair Value
March 31, 2023: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
U.S. Treasury securities and obligations of U.S. government agencies |  | $ | 435,258 | ​ | $ | (3,672) | ​ | $ | 31 |  | $ | 431,617
Bank certificates of deposits | ​ | ​ | 10,355 | ​ | ​ | (187) | ​ | ​ | 1 | ​ | ​ | 10,169
Corporate securities | ​ | ​ | 341,868 | ​ | ​ | (5,370) | ​ | ​ | — | ​ | ​ | 336,498
Municipal securities |  | ​ | 1,544 | ​ | ​ | (1) | ​ | ​ | — |  | ​ | 1,543
​ | ​ | $ | 789,025 | ​ | $ | (9,230) | ​ | $ | 32 | ​ | $ | 779,827
September 30, 2022: | ​ | ​ |  | ​ |  |  | ​ |  |  | ​ |  |
U.S. Treasury securities and obligations of U.S. government agencies | ​ | $ | 804,774 |  | $ | (6,163) |  | $ | 21 | ​ | $ | 798,632
Bank certificates of deposits | ​ | ​ | 8,335 | ​ | ​ | (158) | ​ | ​ | 1 | ​ | ​ | 8,178
Corporate securities | ​ | ​ | 406,270 | ​ | ​ | (8,113) | ​ | ​ | — | ​ | ​ | 398,157
Municipal securities | ​ |  | 59,043 | ​ | ​ | (226) | ​ | ​ | — |  | ​ | 58,817
​ | ​ | $ | 1,278,422 | ​ | $ | (14,660) | ​ | $ | 22 | ​ | $ | 1,263,784

​

The fair values of the marketable securities by contractual maturities at March 31, 2023 are presented below (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Amortized | ​ | ​ | ​
​ |  | ​ | ​ | Cost | ​ | ​ | Fair Value
Due in one year or less | ​ | ​ | ​ | $ | 515,364 | ​ | $ | 513,652
Due after one year through five years | ​ | ​ | ​ |  | 270,591 | ​ |  | 263,105
Due after five years through ten years | ​ | ​ | ​ | ​ | — | ​ | ​ | —
Due after ten years | ​ | ​ | ​ |  | 3,070 | ​ |  | 3,070
Total marketable securities | ​ | ​ | ​ | $ | 789,025 | ​ | $ | 779,827

​

Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties.

The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. Management does not believe any unrealized losses represent impairments based on our evaluation of the available evidence.

​

5. Business Combinations

The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and

17

Table of Contents

assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The finalization of the assignment of fair values will be completed within one year after the respective acquisition date.

Acquisitions Completed in Fiscal Year 2023

​

Ziath Ltd

​

On February 2, 2023, the Company acquired Ziath Ltd and its subsidiaries (‘Ziath’). Based in Cambridge, United Kingdom, Ziath is a leading provider of 2D barcode readers for life sciences applications. Founded in 2005, Ziath’s innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotech and academic customers worldwide. Ziath will enhance the Company’s offerings which support the entire lifecycle of sample management – from specimen collection to sample registration, storage and processing. The acquisition was completed for a purchase price of $16 million, net of cash acquired and the acquired business will be included in the Life Sciences Products segment.

​

The preliminary allocation of the consideration included $12 million of goodwill, $4.1 million of technology, $1.1 million of deferred tax liability, $0.6 million of customer relationships, $0.3 million of trademarks, and several other assets and liabilities. The weighted average life of completed technology is 10 years, customer relationships is 13 years, and trademarks is 13 years. The goodwill represents the Company’s ability to provide a differentiated technology enabling high-throughput scanning of varied formats of consumables. The goodwill is not expected to be deductible for income tax purposes.

​

The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions because such results were immaterial.

​

B Medical Systems S.á r.l.

​

On October 3, 2022, the Company acquired B Medical Systems S.á r.l. and its subsidiaries ("B Medical"), for a purchase price of approximately $432.2 million including contingent consideration, which the Company estimated the fair value to be $17 million as of the measurement date. B Medical is a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. B Medical’s results of operations are reported in the Company’s Life Sciences Products reportable segment from the date of acquisition. The Company paid a total initial cash purchase price at closing of $424 million, as adjusted for cash acquired and other items pursuant to the acquisition agreement. B Medical Systems Holdings S.A (the “Seller”) is eligible to earn up to approximately €50 million in contingent consideration based upon achievement of certain financial metrics by B Medical and its subsidiaries. Included in the purchase price, the Company repaid B Medical’s outstanding debt of $43.1 million prior to September 30, 2022 which was classified in prepaid assets as of September 30, 2022. In addition, as of September 30, 2022, the Company had recorded $381 million in short-term restricted cash, which was reserved to complete the acquisition on October 3, 2022.

The contingent consideration payment is based on achievement of certain revenue targets over the one-year period from October 3, 2022 to September 30, 2023. Pursuant to ASC 805, Business Combinations (“ASC 805”), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter, the Company is required to remeasure the fair value of this liability as assumptions change over time and any resulting adjustments in the fair value of this liability are recorded in “Operating expenses” in the Company’s Consolidated Statements of Operations. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820. This fair value measurement is directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the

18

Table of Contents

Company would record additional charges or gains. As of March 31, 2023, the contingent consideration liability was $1.4 million, as compared to $18.5 million as of December 31, 2022.

The total purchase price was allocated to B Medical’s tangible and identifiable intangible assets and liabilities based on the estimated fair values as of October 3, 2022, as set forth below:

​

​ | ​ | ​ | ​
​ |  | Fair Value of
​ | ​ | Assets and
​ | ​ | Liabilities
Accounts receivable | ​ | ​ | 19,549
Inventory | ​ |  | 49,497
Other assets | ​ |  | 10,769
Property plant and equipment | ​ |  | 54,149
Identifiable Intangible Assets: | ​ |  | ​
Completed technology | ​ |  | 100,600
Trademarks | ​ |  | 5,500
Customer relationships | ​ |  | 36,700
Backlog | ​ |  | 600
Other liabilities | ​ |  | (31,080)
Deferred income taxes, net | ​ | ​ | (42,974)
Goodwill | ​ | ​ | 228,851
Total purchase price, net of cash acquired | ​ | $ | 432,160

​

During the three months ended March 31, 2023, the purchase price, net of cash acquired, remains the same. The Company recorded adjustments which resulted in a net increase to goodwill of $9.8 million. These adjustments include a $1.0 million decrease to property, plant and equipment, a $0.4 million increase to intangible assets, a $9.6 million decrease to other assets, a $0.2 million decrease to inventory and a $0.6 increase in deferred revenue.

In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of B Medical’s business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities. As part of the purchase price allocations, the Company determined the identifiable intangible assets were completed technology, trademarks, customer relationships and backlog. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 13% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with references to the implied rate of return from the transaction and the weighted average cost of capital. The weighted average life of completed technology is 10 years, customer relationships is 16 years, trademarks is 5 years and backlog is 1 year. The intangible assets acquired are amortized over their respective weighted average life using methods that approximate the pattern in which the economic benefits are expected to be realized. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Goodwill of $228.8 million largely reflects the potential expansion of the Company's cold chain capabilities by adding differentiated solutions for reliable and traceable transport of temperature-controlled specimens in the Company's Life Sciences Products reportable segment. The goodwill is no t expected to be deductible for income tax purposes.

The revenues from B Medical included in the Company's consolidated results for the three and six months ended March 31, 2023 were $15.1 million and $57.3 million, respectively. The net loss from B Medical included in the Company's consolidated results for the three and six months ended March 31, 2023 were $10.4 million and $13.0 million, respectively. The Company incurred $8.9 million in transaction costs related to the acquisition of which $0.2 million was incurred during the three months ended March 31, 2023.

The following unaudited pro forma information reflects our consolidated results of operations as if the acquisition had taken place on October 1, 2021. The unaudited pro forma information is not necessarily indicative of the results of

19

Table of Contents

operations that we would have reported had the transaction actually occurred at the beginning of these periods nor is it necessarily indicative of future results.

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended, March 31, | ​ | ​ | ​ | ​ | Six Months Ended, March 31,
​ | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenue | ​ | $ | 148,401 | ​ | $ | ​ | 178,812 | ​ | ​ | ​ | $ | 326,767 | ​ | ​ | $ | 357,433 | ​
Net (loss) income | ​ | ​ | (3,233) | ​ | $ | ​ | 2,117,936 | ​ | ​ | ​ | ​ | (9,078) | ​ | ​ | ​ | 2,150,720 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

To present our consolidated results of operations as if the acquisition had taken place on October 1, 2021, the unaudited pro forma earnings for the three months and six months ended March 31, 2022 have been adjusted to include the following additional expenses related o the acquisition: $6.4 million and $12.7 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense. Non-recurring acquisition related items and significant GAAP adjustments included in the three months and six months ended March 31, 2022 include $8.7 million and $8.9 million, respectively, of transactions costs, $5.4 million and $5.7 million of reversal of debt interest expense, and $1.4 million and $1.6 million expensed as a reversal of research and development capitalization. The unaudited pro forma earnings for the three months and six months ended March 31, 2023 have been adjusted to include the following additional expenses related to the acquisition: $2.7 million and $5.4 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense and non-recurring acquisition of $0.3 million and $4.9 million related to transaction costs. The pro forma information does not include any anticipated cost savings or other effects of the integration of B Medical. Accordingly, the unaudited pro forma information does not necessarily reflect the actual results that would have occurred, nor is it necessarily indicative of future results of operations

​

Acquisition Completed in Fiscal Year 2022

​

Barkey Holding GmbH

​

On July 1, 2022, the Company acquired Barkey Holding GmbH and its subsidiaries (“Barkey”), a leading provider of controlled-rate thawing devices for customers in the medical, biotech and pharmaceutical industries, head quartered in Leopoldshöhe, Germany. The Company has included the financial results of the acquired operations within the Life Sciences Products segment. The total cash purchase price of the acquisition was approximately $84.8 million, net of cash acquired. The acquisition brings innovative products and capabilities that extend the Company’s extensive cold chain of condition portfolio of products and services, while also expanding our customer reach in the fast-growing cell and gene therapy space. The allocation of the consideration included $3.0 million of customer relationships, $29.0 million of technology, $57.8 million of goodwill, $9.8 million of deferred tax liabilities, and several other assets and liabilities. The weighted useful life of all the intangible assets acquired is 15 years. The goodwill and intangibles are not tax deductible.

The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions completed in fiscal year 2022 because such results were immaterial.

​

6. Goodwill and Intangible Assets

Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of the businesses acquired by the Company. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. The Company has elected April 1st as its annual goodwill impairment assessment date. If the existence of events or circumstances indicates that it is more likely than not that fair values of the

20

Table of Contents

reporting units are below their carrying values, the Company performs additional impairment tests during interim periods to evaluate goodwill for impairment.

Application of the goodwill impairment test requires significant judgment based on market and operational conditions at the time of the evaluation, including management’s best estimate of future business activity and the related estimates of future cash flows from the assets and the reporting units that include the associated goodwill. These periodic evaluations could cause management to conclude that impairment factors exist, requiring an adjustment of these assets to their then current fair market values. Future business conditions and/or activity could differ materially from the projections made by management which could result in impairment charges.

The goodwill impairment test is performed at the reporting unit level. A reporting unit is either an operating segment or one level below it, which is referred to as a “component”. The level at which the impairment test is performed requires an assessment of whether the operations below an operating segment constitute a self-sustaining business, in which case testing is generally performed at this level.

In accordance with ASC 350, Intangibles-Goodwill and Other (“ASC 350”), the Company first assesses qualitative factors to determine whether the existence of events or circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines, based on this assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying value, it performs a quantitative goodwill impairment test by comparing the reporting unit’s fair value with its carrying value. An impairment loss is recognized for the amount by which the reporting unit’s carrying value exceeds its fair value, up to the total amount of goodwill allocated to the reporting unit.

We determine fair values of our reporting units based on an income approach in accordance with the discounted cash flow method, or DCF Method. The DCF Method is based on projected future cash flows and terminal value estimates discounted to their present values. Terminal value represents the present value an investor would pay on the valuation date for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. We consider the DCF Method to be the most appropriate valuation technique since it is based on management’s long-term financial projections. In addition to determining the fair value of our reporting units based on the DCF Method, we also compare the aggregate values of our net corporate assets and reporting unit fair values to our overall market capitalization and use certain market-based valuation techniques to assess the reasonableness of the reporting unit fair values determined in accordance with the DCF Method. The key inputs used in the DCF Method include revenue growth rates, gross margin percentage, selling, general and administrative expense percentage and discount rates that are at or above our weighted average cost of capital. We derive discount rates that are commensurate with the risks and uncertainties inherent in the respective reporting units and our internally developed projections of future cash flows.

Application of the goodwill impairment test requires judgment based on market and operational conditions at the time of the evaluation, including management’s best estimates of the reporting unit’s future business activity and the related estimates and assumptions of future cash flows from the assets that include the associated goodwill. Different assumptions of revenue growth rates, gross margin percentage, selling, general and administrative expense percentage and the discount rate used in the DCF Method could result in different estimates of the reporting unit’s fair value as of each testing date.

In the second quarter of 2023, as part of the Company’s routine long-term planning process, the Company assessed several events and circumstances that could affect the significant inputs used to determine the fair value of its reporting units, including updates to forecasted margins and cash flows, and the overall change in the economic climate since our last impairment assessment. The Company considered the impairment indicators as described in ASC 350 and determined it appropriate to perform a quantitative assessment of both its reporting units as of March 31, 2023. The estimated fair value of the Life Sciences Services and Life Sciences Products reporting units exceeded their respective carrying values by approximately 24% and 17%, respectively as of March 31, 2023. Therefore, the Company concluded that there was no impairment to goodwill.

In the event the financial performance of either of the reporting units does not meet our expectations in the future, we experience a prolonged macroeconomic or market downturn, declines in our stock price, or there are other negative

21

Table of Contents

revisions to key assumptions used in our DCF Method, we may be required to perform additional impairment analyses and could be required to recognize an impairment charge.

Please refer to Note 8, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2022 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2022.

The changes in the Company’s goodwill by reportable segment for the six months ended March 31, 2023 are as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | ​ | ​
​ | ​ | Life Sciences | ​ | Life Sciences | ​ | ​ | ​
​ | ​ | Products | ​ | Services | ​ | Total
Balance, at September 30, 2022 | ​ | $ | 154,612 | ​ | $ | 359,011 | ​ | $ | 513,623
Acquisitions | ​ |  | 228,851 | ​ |  | — | ​ |  | 228,851
Currency translation adjustments | ​ | ​ | 47,998 | ​ | ​ | 22 | ​ | ​ | 48,020
Balance, at March 31, 2023 | ​ | $ | 431,461 | ​ | $ | 359,033 | ​ | $ | 790,494

​

During the six months ended March 31, 2023, the Company recorded goodwill related to the B Medical and Ziath acquisitions of $228.9 million and an increase in goodwill of $48.0 million related to foreign currency translation adjustments.

​

The components of the Company’s identifiable intangible assets as of March 31, 2023 and September 30, 2022 are as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, 2023 | ​ | September 30, 2022
​ | ​ | ​ | ​ | Accumulated | ​ | Net Book | ​ | ​ | ​ | Accumulated | ​ | Net Book
​ |  | Cost |  | Amortization |  | Value |  | Cost |  | Amortization |  | Value
Patents | ​ | $ | 8,996 | ​ | $ | 8,911 | ​ | $ | 85 | ​ | $ | 1,225 | ​ | $ | 1,106 | ​ | $ | 119
Completed technology | ​ |  | 258,146 | ​ |  | 85,726 | ​ |  | 172,420 | ​ |  | 99,525 | ​ |  | 37,991 | ​ |  | 61,534
Trademarks and trade names | ​ |  | 8,848 | ​ |  | 2,865 | ​ |  | 5,983 | ​ |  | 400 | ​ |  | 41 | ​ |  | 359
Non-competition agreements | ​ | ​ | 731 | ​ | ​ | 553 | ​ | ​ | 178 | ​ | ​ | 681 | ​ | ​ | 439 | ​ | ​ | 242
Customer relationships | ​ |  | 321,024 | ​ |  | 176,432 | ​ |  | 144,592 | ​ |  | 246,949 | ​ |  | 130,802 | ​ |  | 116,147
Other intangibles | ​ | ​ | 896 | ​ | ​ | 227 | ​ | ​ | 669 | ​ | ​ | 202 | ​ | ​ | 202 | ​ | ​ | —
​ | ​ | $ | 598,641 | ​ | $ | 274,714 | ​ | $ | 323,927 | ​ | $ | 348,982 | ​ | $ | 170,581 | ​ | $ | 178,401

​

During the six months ended March 31, 2023, the Company recorded intangible assets related to the B Medical and Ziath acquisitions of $150.3 million.

​

Amortization expense for intangible assets was $12.4 million and $7.9 million, respectively, for the three months ended March 31, 2023 and 2022. Amortization expense for intangible assets was $24.0 million and $15.9 million, for the six months ended March 31, 2023 and 2022, respectively.

​

22

Table of Contents

Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2023, the subsequent four fiscal years and thereafter is as follows (in thousands):

​ | ​ | ​ | ​
2023 | ​ | $ | 24,217
2024 | ​ |  | 50,542
2025 | ​ |  | 49,151
2026 | ​ |  | 45,754
2027 | ​ | ​ | 37,573
Thereafter | ​ | ​ | 116,690
Total | ​ | $ | 323,927

​

​

​

23

Table of Contents

7. Leases

The Company has operating leases for real estate and non-real estate and finance leases for non-real estate in North America, Europe, and Asia. Non-real estate leases are primarily related to vehicles and office equipment. Lease expiration dates range between 2023 and 2042.

The components of lease expense were as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
​ | ​ | ​ | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating lease costs | ​ | ​ | ​ | $ | 3,086 | ​ | $ | 2,389 | ​ | $ | 6,150 | ​ | $ | 4,560 | ​
Finance lease costs: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of assets | ​ | ​ | ​ | ​ | 151 | ​ | ​ | 54 | ​ | ​ | 242 | ​ | ​ | 129 | ​
Interest on lease liabilities | ​ | ​ | ​ | ​ | 9 | ​ | ​ | 2 | ​ | ​ | 13 | ​ | ​ | 5 | ​
Total finance lease costs | ​ | ​ | ​ | ​ | 160 | ​ | ​ | 56 | ​ | ​ | 255 | ​ | ​ | 134 | ​
Variable lease costs | ​ | ​ | ​ | ​ | - | ​ | ​ | 755 | ​ | ​ | 2 | ​ | ​ | 1,272 | ​
Short-term lease costs | ​ | ​ | ​ | ​ | 226 | ​ | ​ | 364 | ​ | ​ | 410 | ​ | ​ | 718 | ​
Sublease income | ​ | ​ | ​ | ​ | (2) | ​ | ​ | - | ​ | ​ | (4) | ​ | ​ | - | ​
Total lease costs | ​ | ​ | ​ | $ | 3,470 | ​ | $ | 3,564 | ​ | $ | 6,813 | ​ | $ | 6,684 | ​

​

Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | March 31, 2023 | ​ | September 30, 2022 | ​
Operating Leases: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating lease right-of-use assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 63,122 | ​ | $ | 54,059 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accrued expenses and other current liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 8,778 | ​ | $ | 6,924 | ​
Long-term operating lease liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 57,137 | ​ | ​ | 49,227 | ​
Total operating lease liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 65,915 | ​ | $ | 56,151 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Finance Leases: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Property, plant and equipment, at cost | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 4,010 | ​ | $ | 2,476 | ​
Accumulated amortization | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (2,504) | ​ | ​ | (2,276) | ​
Property, plant and equipment, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,506 | ​ | $ | 200 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accrued expenses and other current liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 543 | ​ | $ | 96 | ​
Other long-term liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,129 | ​ | ​ | 98 | ​
Total finance lease liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,672 | ​ | $ | 194 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average remaining lease term (in years): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating leases | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10.10 | ​ | ​ | 10.82 | ​
Finance leases | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3.46 | ​ | ​ | 2.19 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average discount rate: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating leases | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4.04 | % | ​ | 3.93 | %
Finance leases | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2.44 | % | ​ | 1.29 | %

​

24

Table of Contents

Supplemental cash flow information related to leases was as follows (in thousands, unaudited):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
​ | ​ | ​ | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​
Cash paid for amounts included in measurement of liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating cash flows from operating leases | ​ | ​ | ​ | $ | 2,631 | ​ | $ | 1950 | ​ | $ | 5,200 | ​ | $ | 3,599 | ​
Operating cash flows from finance leases | ​ | ​ | ​ | ​ | 9 | ​ | ​ | 1 | ​ | ​ | 13 | ​ | ​ | 4 | ​
Financing cash flows from finance leases | ​ | ​ | ​ | ​ | 139 | ​ | ​ | 127 | ​ | ​ | 226 | ​ | ​ | 312 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ROU assets obtained in exchange for lease liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating leases | ​ | ​ | ​ | $ | 7,230 | ​ | $ | 7,327 | ​ | $ | 6,464 | ​ | $ | 7,490 | ​
Finance leases | ​ | ​ | ​ | ​ | 270 | ​ | ​ | - | ​ | ​ | 1,060 | ​ | ​ | - | ​

​

​

Future lease payments for operating and finance leases as of March 31, 2023 were as follows for the remainder of fiscal year 2023, the subsequent four fiscal years and thereafter (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Finance Leases | Operating Leases | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2023 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 298 | ​ | $ | 5,779 | ​
2024 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 540 | ​ | ​ | 10,613 | ​
2025 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 450 | ​ | ​ | 10,316 | ​
2026 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 308 | ​ | ​ | 7,974 | ​
2027 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 135 | ​ | ​ | 7,552 | ​
Thereafter | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 17 | ​ | ​ | 39,860 | ​
Total future lease payments | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,748 | ​ | ​ | 82,094 | ​
Less imputed interest | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (76) | ​ | ​ | (16,179) | ​
Total lease liability balance | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 1,672 | ​ | $ | 65,915 | ​

As of March 31, 2023, the Company did not have significant leases that have not commenced or not recorded in the accompanying unaudited Consolidated Balance Sheets.

​

8. Income Taxes

The Company recorded an income tax benefit of $3.3 million and $7.9 million, respectively during the three and six months ended March 31, 2023. The tax benefit for the three months ended March 31, 2023 was primarily driven by the pre-tax loss from operations during the period. The tax benefit for the six months ended March 31, 2023 was primarily driven by the pre-tax loss from operations and a $1.4 million deferred tax benefit resulting from the extension of a tax incentive in China. The effective tax rates for the three and six months ended March 31, 2023 are substantially higher than statutory rates. The effective rates are driven higher than statutory rates by the discrete tax benefit in China noted above and the fair value adjustment of the contingent consideration related to the B Medical acquisition. The contingent consideration generated $17.1 million of pre-tax income that is not subject to income taxes, therefore, the tax benefit is being driven by a tax loss that is significantly higher than the book loss for these periods. The effective tax rate on a six-month basis without these discrete events is slightly higher than average statutory tax rates due to the jurisdictional mix of income with losses being generated in higher tax jurisdictions and income being generated in lower jurisdictions.

​

The Company recorded an income tax benefit of $3.2 million and $7.9 million, respectively, during the three and six months ended March 31, 2022. The tax benefit for the three months ended March 31, 2022 was primarily driven by the benefit on loss from operations during the period. The tax benefit for the six months ended March 31, 2022 was increased by a $4.5 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The tax benefit for the six months ended March 31, 2022 was partially offset by a $0.6 million charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets. The effective tax rates for the three and six months ended March 31,

25

Table of Contents

2022 were significantly higher than the statutory rates. The higher effective rates were driven by the tax benefit on the stock compensation deduction and near break-even pre-tax losses of $1.8 million and $5.0 million, respectively, in the 2023 periods.

​

The Company evaluates the realizability of its deferred tax assets by tax-paying component and assesses the need for a valuation allowance on an annual and a quarterly basis. The Company evaluates the profitability of each tax-paying component on a historical cumulative basis and a forward-looking basis in the course of performing this analysis. The Company maintains a U.S. valuation allowance related to the realizability of certain state tax credits and state net operating loss carry-forwards, as well as a valuation allowance against net deferred tax assets on certain foreign tax-paying components as of March 31, 2023. The Company has generated recent pre-tax tax losses but is in an overall deferred tax liability position where future taxable temporary differences are sufficient to offset future deductible temporary differences. The Company continues to monitor historical cumulative income and may record an adjustment to the valuation allowance if there is a shift to the deferred tax asset position in a future period.

The Company maintains liabilities for unrecognized tax benefits. These liabilities involve judgment and estimation, and they are monitored based on the best information available. The Company recognizes interest related to unrecognized tax benefits as a component of the income tax provision or benefit. The Company recognized minimal interest expense related to its unrecognized tax benefits during the three and six months ended March 31, 2023.

The Company is subject to U.S. federal, state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company’s interpretation of applicable tax laws in the jurisdictions in which it files.

In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the U.S. and international jurisdictions, with the earliest tax year being 2017. Based on the outcome of these examinations or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Company’s Consolidated Balance Sheets. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefits and accrued interest on those benefits will be reduced by $1.4 million in the next twelve months due to statute of limitations expirations. These unrecognized tax benefits would impact the effective tax rate if recognized.

​

​

9. Other Balance Sheet Information

The following is a summary of accounts receivable at March 31, 2023 and September 30, 2022 (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | September 30, | ​
​ |  | 2023 |  | 2022 |
Accounts receivable | ​ | $ | 175,656 | ​ | $ | 168,920 | ​
Less allowance for expected credit losses | ​ |  | (7,696) | ​ |  | (5,162) | ​
Accounts receivable, net | ​ | $ | 167,960 | ​ | $ | 163,758 | ​

​

​

The allowance for expected credit losses for the six months ended March 31, 2023 and fiscal year ended September 30, 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Balance at | ​ | ​ | ​ | ​ | Reversals of | ​ | Write- | ​ | Balance at
​ | ​ | Beginning of | ​ | ​ | ​ | ​ | Bad Debt | ​ | offs and | ​ | End of
Description |  | Period |  | Provisions |  | Expense |  | Adjustments |  | Period
Six months ended March 31, 2023 allowance for expected credit losses | ​ | $ | 5,162 | ​ | ​ | 4,858 | ​ | ​ | (2,254) | ​ | $ | (70) | ​ | $ | 7,696
Fiscal year 2022 allowance for expected credit losses | ​ |  | 4,318 | ​ | ​ | 3,020 | ​ | ​ | (2,510) | ​ | $ | (414) | ​ | ​ | 4,414

26

Table of Contents

​

The following is a summary of inventories at March 31, 2023 and September 30, 2022 (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30, | ​
​ |  | 2023 |  | 2022 |
Inventories |  | ​ |  |  |  |  |
Raw materials and purchased parts |  | $ | 71,912 |  | $ | 39,685 | ​
Work-in-process |  | ​ | 5,065 |  | ​ | 4,816 | ​
Finished goods |  | ​ | 73,750 |  | ​ | 41,043 | ​
Total inventories |  | $ | 150,727 |  | $ | 85,544 | ​

​

​

Reserves related to write downs or adjustments of inventory to net realizable value were $4.1 million and $4.1 million, respectively, at March 31, 2023 and September 30, 2022.

At March 31, 2023 and September 30, 2022, the Company had cumulative capitalized direct costs of $28.7 million and $26.9 million, respectively, associated with the development of software for its internal use. As of March 31, 2023, this balance included $10.2 million associated with software assets that are still in the development stage and not yet placed in service. During the three and six months ended March 31, 2023, the Company capitalized direct costs associated with the development of software for its internal use of $0.7 million and $1.8 million, respectively, as compared to $0.8 million and $1.3 million, respectively, during the corresponding period of the prior fiscal year.

The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company.

27

Table of Contents

The following is a summary of product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2023 and 2022 (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Activity -Three Months Ended March 31, 2023
Balance | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Balance
December 31, | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | March 31,
2022 | ​ | ​ | Adjustments for Acquisitions | ​ | Accruals | ​ | Costs Incurred | ​ | 2023
$ | 5,179 | ​ | ​ | — | ​ | $ | 1,222 | ​ | $ | (1,021) | ​ | $ | 5,380
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Activity -Three Months Ended March 31, 2022
Balance | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Balance
December 31, | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | March 31,
2021 | ​ | ​ | Adjustments for Acquisitions | ​ | Accruals | ​ | Costs Incurred | ​ | 2022
$ | 2,342 | ​ | ​ | — | ​ | $ | 539 | ​ | $ | (390) | ​ | $ | 2,491
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Activity -Six Months Ended March 31, 2023
Balance | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Balance
September 30, | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | March 31,
2022 | ​ | ​ | Adjustments for Acquisitions | ​ | Accruals | ​ | Costs Incurred | ​ | 2023
$ | 2,890 | ​ | ​ | 2,303 | ​ | $ | 1,529 | ​ | $ | (1,342) | ​ | $ | 5,380
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Activity -Six Months Ended March 31, 2022
Balance | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | Balance
September 30, | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | March 31,
2021 | ​ | ​ | Adjustments for Acquisitions | ​ | Accruals | ​ | Costs Incurred | ​ | 2022
$ | 2,330 | ​ | ​ | — | ​ | $ | 1,212 | ​ | $ | (1,051) | ​ | $ | 2,491

​

10. Stock-Based Compensation

The Company may issue to eligible employees options to purchase shares of the Company’s stock, restricted stock and other equity incentives which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan, and stock awards and deferred restricted stock units to its directors in accordance with its director compensation program.

The stock-based compensation expense for restricted stock units for continuing operations was $3.9 million and $5.2 million, for the three months ended March 31, 2023 and 2022, respectively. The stock-based compensation expense for restricted stock units for continuing operations was $5.8 million and $7.7 million for the six months ended March 31, 2023 and 2022, respectively. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.4 million and $0.4 million, respectively, for the three months ended March 31, 2023 and 2022. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.7 million and $0.8 million, respectively, for the six months ended March 31, 2023 and 2022.

The information included within the remaining note is on a total company basis, and includes amounts related to our discontinued operations.

28

Table of Contents

The following table reflects the total stock-based compensation expense recorded during the three and six months ended March 31, 2023 and 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
​ |  | 2023 |  | 2022 |  | 2023 |  | 2022 |
Restricted stock units | ​ | $ | 3,634 | ​ | $ | 8,058 | ​ | $ | 5,393 | ​ | $ | 15,255 | ​
Employee stock purchase plan | ​ |  | 356 | ​ |  | 599 | ​ |  | 703 | ​ |  | 1,293 | ​
Total stock-based compensation expense | ​ | $ | 3,990 | ​ | $ | 8,657 | ​ | $ | 6,096 | ​ | $ | 16,548 | ​

​

The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusted for the probability percentage of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Each quarter, the Company assesses the probability of achieving the performance goals. Current estimates may differ from actual results and future changes in estimates.

The Company grants restricted stock units that vest over a required service period and/or achievement of certain operating performance goals. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units and stock awards granted during the six months ended March 31, 2023 and 2022:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Time-Based |  | Stock |  | Performance-
​ | ​ | Total Units | ​ | Units | ​ | Grants | ​ | Based Units
Six months ended March 31, 2023 |  | 572,111 |  | 356,410 |  | — |  | 215,701
Six months ended March 31, 2022 |  | 228,468 | ​ | 101,706 |  | 16,286 |  | 110,476

​

Time-Based Restricted Stock Unit Grants

Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third of awards vest at the first anniversary of the grant date, one-third vest at the second anniversary of the grant date and one-third vest at the third anniversary of the grant date, subject to the award holders meeting service requirements.

Stock-Based Awards – Board of Directors

The stock-based awards granted to the members of the Company’s Board of Directors include stock awards, restricted stock awards, deferred stock and restricted stock units.

Certain members of the Board of Directors have elected to defer receiving their annual stock awards and related quarterly dividends, if any, until they attain a certain age or cease to provide services as a member of the Company’s Board of Directors. Annual deferred restricted stock units granted during fiscal years 2023 and 2022 were vested upon issuance.

Performance-Based Restricted Stock Unit Grants

Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals.

29

Table of Contents

Performance-based awards granted in fiscal year 2023, 2022 and 2021 allow participants to earn 100% of the restricted stock units if the Company’s performance meets or exceeds its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals will be measured over a three-year period for each year’s awards and at the end of the period to determine the number of units earned by recipients who continue to meet the service requirement. Around the third anniversary of each year’s awards’ grant date, the Company’s Board of Directors determines the number of units earned for participants who continue to meet the service requirements on the vest date.

Restricted Stock Unit Activity

The following table summarizes restricted stock unit activity for the six months ended March 31, 2023:

​

​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | Grant-Date
​ | ​ | Shares | ​ | Fair Value
Outstanding at September 30, 2022 |  | 538,238 | ​ | $ | 71.99
Granted |  | 572,111 | ​ | ​ | 58.21
Vested |  | (261,618) | ​ | ​ | 55.66
Forfeited |  | (81,878) | ​ | ​ | 78.66
Outstanding at March 31, 2023 |  | 766,853 | ​ | ​ | 67.68

​

The weighted average grant date fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $58.21 and $82.34, respectively. The fair value of restricted stock units vested during the three months ended March 31, 2023 and 2022 was $2.6 million and $1.9 million, respectively. During the six months ended March 31, 2023 and 2022, the Company remitted $4.9 million and $25.1 million, respectively, to satisfy employee tax obligations as a result of share issuances, of which $4.9 million and $0, respectively, was paid by the Company. During the three months ended March 31, 2023 and 2022, the Company remitted $0 million and $0 million, respectively, from employees to satisfy their tax obligations as a result of share issuances.

As of March 31, 2023, the unrecognized compensation cost that are expected to vest is $31.1 million and will be recognized over an estimated weighted average service period of approximately 2.04 years.

Employee Stock Purchase Plan

The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual offering period, whichever is lower. There were 39,479 and 51,133 shares, respectively, purchased by employees under the employee stock purchase plan during the six months ended March 31, 2023 and 2022.

​

11. Stockholders’ Equity

On November 4, 2022, the Company’s Board of Directors terminated the Company’s then existing $50 million share repurchase authorization and approved a new authorization to repurchase up to $1.5 billion of shares of the Company’s common stock from time to time through open market or through privately negotiated transactions (including under an accelerated share repurchase, referred to as an ASR, agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market and business conditions, legal requirements, and other factors. The repurchase program can be discontinued at any time.

​

On November 23, 2022, the Company executed an Accelerated Share Repurchase Agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (the “Dealer”) to repurchase an aggregate of up to

30

Table of Contents

$500.0 million of the Company’s common stock. Under the terms of the ASR Agreement, the Company made a payment of $500.0 million to the Dealer on November 28, 2022 and received an initial delivery of approximately 6.1 million shares of common stock from the Dealer, representing approximately 70% of the total shares of common stock that were expected to be repurchased under the ASR Agreement. The final number of shares repurchased by the Company was based on the average of the daily volume-weighted average price of the Company’s common stock during the term of the ASR Agreement, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreement. The final settlement of the transactions under the ASR Agreement occurred in April 2023 following the completion of the Company’s second fiscal quarter, and the Company received 4 million additional shares of common stock from the Dealer as of the settlement date. The Company evaluated the nature of the forward contract aspect of the ASR Agreement under ASC 815, Derivatives and Hedging, and concluded equity classification was appropriate. The shares of common stock repurchased by the Company under the ASR Agreement were retired, accounted for as a reduction to stockholders’ equity in the Company’s Consolidated Balance Sheets and treated as a repurchase of common stock for purposes of calculating earnings per share as of the applicable settlement date.

As of March 31, 2023, after giving effect to the ASR Agreement, approximately $1.0 billion of the amount authorized remained available for additional repurchases of the Company’s common stock. Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which the Company expects to repurchase up to an additional $500 million shares of common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

12. Earnings per Share

The calculations of basic and diluted net income (loss) per share and basic and diluted weighted average shares outstanding are as follows for the three and six months ended March 31, 2023 and 2022 (in thousands, except per share data):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Six Months Ended | ​
​ | ​ | March 31, | ​ | March 31, | ​
​ |  | 2023 |  | 2022 |  | 2023 |  | 2022 |
Income (loss) from continuing operations | ​ | $ | (1,991) | ​ | $ | (1,816) | ​ | $ | (13,226) | ​ | $ | 1,041 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (2,936) | ​ |  | 2,121,690 | ​ |  | (2,936) | ​ |  | 2,162,152 | ​
Net income (loss) | ​ | $ | (4,927) | ​ | $ | 2,119,874 | ​ | $ | (16,162) | ​ | $ | 2,163,193 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average common shares outstanding used in computing basic income (loss) per share | ​ |  | 69,111 | ​ |  | 74,958 | ​ |  | 70,858 | ​ |  | 74,823 | ​
Dilutive restricted stock units | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 322 | ​
Weighted average common shares outstanding used in computing diluted income (loss) per share | ​ |  | 69,111 | ​ |  | 74,958 | ​ |  | 70,858 | ​ |  | 75,145 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic net income (loss) per share: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Income (loss) from continuing operations | ​ | $ | (0.03) | ​ | $ | (0.02) | ​ | $ | (0.19) | ​ | $ | 0.01 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (0.04) | ​ |  | 28.31 | ​ |  | (0.04) | ​ |  | 28.90 | ​
Basic net income (loss) per share | ​ | $ | (0.07) | ​ | $ | 28.28 | ​ | $ | (0.23) | ​ | $ | 28.91 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Diluted net income (loss) per share: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |  | ​
Income (loss) from continuing operations | ​ | $ | (0.03) | ​ | $ | (0.02) | ​ | $ | (0.19) | ​ | $ | 0.01 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (0.04) | ​ |  | 28.31 | ​ |  | (0.04) | ​ |  | 28.77 | ​
Diluted net income (loss) per share | ​ | $ | (0.07) | ​ | $ | 28.28 | ​ | $ | (0.23) | ​ | $ | 28.79 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

31

Table of Contents

During the six months ended March 31, 2022, 59,513 restricted stock units were excluded from the computation of diluted loss per share as their effect would be antidilutive to earnings per share for continuing operations based on the treasury stock method.

​

13. Revenue from Contracts with Customers

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three and six months ended March 31, 2023 and 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Three months ended March 31, | ​ | ​ | Six months ended March 31,
​ | ​ | ​ | ​ | 2023 | ​ | ​ | 2022 | ​ | ​ | ​ | 2023 | ​ | 2022
Significant Business Line | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Products, excluding B Medical | ​ | ​ | ​ | $ | 43,738 | ​ | ​ | $ | 53,615 | ​ | ​ | $ | 91,576 | ​ | $ | 103,493
B Medical | ​ | ​ | ​ | ​ | 15,122 | ​ | ​ | ​ | - | ​ | ​ | ​ | 56,944 | ​ | ​ | -
Sample Repository Solutions | ​ | ​ | ​ | ​ | 27,305 | ​ | ​ | ​ | 26,929 | ​ | ​ | ​ | 54,921 | ​ | ​ | 52,805
Genomic Services | ​ | ​ | ​ | ​ | 62,236 | ​ | ​ | ​ | 65,000 | ​ | ​ | ​ | 123,326 | ​ | ​ | 128,898
Total | ​ | ​ | ​ | $ | 148,401 | ​ | ​ | $ | 145,544 | ​ | ​ | $ | 326,767 | ​ | $ | 285,196

​

​

Contract Balances

Accounts Receivable, net allowance for expected credit losses. Accounts receivable represent rights to consideration in exchange for products or services that have been transferred by the Company, when payment is unconditional and only the passage of time is required before payment is due. Accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of probable credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance for expected credit losses based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information through the payment periods. Accounts receivable, net of expected credit losses were $168.0 million and $163.8 million at March 31, 2023 and September 30, 2022, respectively.

Contract Assets. Contract assets represent rights to consideration in exchange for products or services that have been transferred by the Company, when payment is conditional on something other than the passage of time. These amounts typically relate to contracts where the right to invoice the customer is not present until completion of the contract or the achievement of specified milestones and the value of the products or services transferred exceed this constraint. Contract assets are classified as current as they convert to cash within one year. Contract asset balances which are included within “Prepaid expenses and other current assets” on the Company’s Consolidated Balance Sheet, were $22.7 million and $18.2 million at March 31, 2023 and September 30, 2022, respectively.

​

Contract Liabilities. Contract liabilities represent the Company’s obligation to transfer products or services to a customer for which consideration has been received, or for which an amount of consideration is due from the customer. Contract assets and liabilities are reported on a net basis at the contract level, depending on the contracts position at the end of each reporting period. Contract liabilities are included within “Deferred revenue” on the Company’s Consolidated Balance Sheet. Contract liabilities were $46.0 million and $39.7 million at March 31, 2023 and September 30, 2022, respectively. The Company recognized $22.4 million and $18.2 million in revenue during the six months ended March 31, 2023 and March 31, 2022, respectively, from contract liability.

​

Remaining Performance Obligations. Remaining performance obligations represent the transaction price of unsatisfied or partially satisfied performance obligations within contracts with an original expected contract term that is greater than one year and for which fulfillment of the contract has started as of the end of the reporting period. The

32

Table of Contents

aggregate amount of transaction consideration allocated to remaining performance obligations as of March 31, 2023 was $91.5 million. The following table summarizes when the Company expects to recognize the remaining performance obligations as revenue; the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of March 31, 2023
​ | ​ | Less than 1 Year | ​ | Greater than 1 Year | ​ | Total
Remaining Performance Obligations | ​ | $ | 58,944 | ​ | $ | 32,516 | ​ | $ | 91,460
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Cost to Obtain and Fulfill a Contract

The Company capitalizes sales commissions when incurred if they are (i) incremental costs of obtaining a contract, (ii) expected to be recovered and (iii) have an expected amortization period that is greater than one year. As part of the Company’s cumulative effect adjustment upon the initial adoption of ASC 606, incremental costs associated with obtaining a contract were capitalized and have been classified as deferred commissions within the Company’s Consolidated Balance Sheet. These amounts primarily relate to sales commissions and are being amortized over a 60-month period, which represents the average period of contract performance. The Company did not capitalize any sales commissions during the six months ended March 31, 2023 and 2022 as the amount of sales commissions that qualified for capitalization during the reporting period was insignificant. Sales commissions incurred during the reporting period have been expensed as incurred. These costs are recorded within “Selling, general and administrative” expenses on the Company’s Consolidated Statement of Operations. The Company has concluded that none of its costs incurred in fulfillment of customer contracts meet the capitalization criteria. The Company will account for shipping and handling activities as fulfillment activities and recognize the associated expense when control of the product has transferred to the customer.

​

14. Segment and Geographic Information

Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker.

The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in three reportable segments: the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment.

The Company’s Life Sciences Products segment provides automated cold storage solutions for biological and chemical compound samples. The Company’s storage systems provide reliable automation and sample inventory management at temperatures down to -190°C and can store anywhere from one to millions of samples. The Company’s sample management solutions include consumable vials and tubes, polymerase chain reaction (PCR), plates, instruments for supporting workflows, and informatics. This portfolio provides customers with the highest level of sample quality, security, availability, intelligence, and integrity throughout the lifecycle of samples providing customers with complete end-to-end “cold-chain of custody” capabilities. The Company also provides controlled rate thawing devices for customers in the medical, biotech and pharmaceutical industries. On October 3, 2022, the Company acquired B Medical, a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to people in more than 150 countries worldwide. On February 2, 2023, the Company acquired Ziath a leading provider of 2D barcode readers for life sciences applications. Both of the acquired businesses are part of the Company’s Life Sciences Products segment.

​

The Company’s Life Sciences Services business is a leading provider of solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research and development markets. The Company processes millions of

33

Table of Contents

samples every year, each containing valuable information that must be delivered or preserved with the sample. The Company’s genomic services provide a broad capability to customers for sequencing and synthesis of genes. The Company’s sample management services include off-site storage services, transport services, laboratory services, and interactive informatics solutions. The storage services include short- and long-term sample storage and management of the “cold chain of custody” from collection, to storage, to retrieving the sample which ultimately may go back into the research workflow.

The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the purchase accounting impact on inventory, amortization of other intangible assets, restructuring related charges, contingent consideration fair value adjustments, tariff adjustment, other unallocated corporate expenses, as the primary performance metric when evaluating the business.

The following is the summary of the financial information for the Company’s reportable segments for the three and six months ended March 31, 2023 and 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
​ | ​ | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​
Revenue: |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | ​
Life Sciences Products | ​ | ​ | $ | 58,860 | ​ | $ | 53,615 | ​ | $ | 148,520 | ​ | $ | 103,487 | ​
Life Sciences Services | ​ | ​ |  | 89,541 | ​ |  | 91,929 | ​ |  | 178,247 | ​ |  | 181,709 | ​
Total revenue | ​ | ​ | $ | 148,401 | ​ | $ | 145,544 | ​ | $ | 326,767 | ​ | $ | 285,196 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income / (loss): | ​ | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Products | ​ | ​ | $ | (16,404) | ​ | $ | 5,288 | ​ | $ | (20,202) | ​ | $ | 9,679 | ​
Life Sciences Services | ​ | ​ |  | (4,878) | ​ |  | 4,856 | ​ |  | (9,490) | ​ |  | 12,740 | ​
Reportable segment operating income (loss) | ​ | ​ | ​ | (21,282) | ​ | ​ | 10,144 | ​ | ​ | (29,692) | ​ | ​ | 22,419 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of completed technology | ​ | ​ | ​ | 4,901 | ​ | ​ | 1,840 | ​ | ​ | 9,070 | ​ | ​ | 3,613 | ​
Purchase accounting impact on inventory | ​ | ​ | ​ | 2,912 | ​ | ​ | — | ​ | ​ | 5,781 | ​ | ​ | — | ​
Amortization of other intangible assets | ​ | ​ | ​ | 7,509 | ​ | ​ | 6,047 | ​ | ​ | 14,882 | ​ | ​ | 12,319 | ​
Restructuring charges | ​ | ​ | ​ | 1,499 | ​ | ​ | 122 | ​ | ​ | 2,961 | ​ | ​ | 295 | ​
Contingent consideration - fair value adjustments | ​ | ​ | ​ | (17,145) | ​ | ​ | — | ​ | ​ | (17,145) | ​ | ​ | — | ​
Tariff adjustment | ​ | ​ | ​ | — | ​ | ​ | (486) | ​ | ​ | — | ​ | ​ | (486) | ​
Other unallocated corporate expenses | ​ | ​ | ​ | (7,981) | ​ | ​ | 7,329 | ​ | ​ | (4,579) | ​ | ​ | 11,711 | ​
Total operating income (loss) | ​ | ​ | ​ | (12,977) | ​ | ​ | (4,708) | ​ | ​ | (40,662) | ​ | ​ | (5,033) | ​
Interest income | ​ | ​ | ​ | 10,394 | ​ | ​ | 3,076 | ​ | ​ | 21,059 | ​ | ​ | 3,111 | ​
Interest expense | ​ | ​ | ​ | — | ​ | ​ | (1,555) | ​ | ​ | — | ​ | ​ | (2,010) | ​
Loss on extinguishment of debt | ​ | ​ | ​ | — | ​ | ​ | (632) | ​ | ​ | — | ​ | ​ | (632) | ​
Other income (expense) | ​ | ​ | ​ | (2,668) | ​ | ​ | (1,170) | ​ | ​ | (1,523) | ​ | ​ | (2,248) | ​
(Loss) before income taxes | ​ | ​ | $ | (5,251) | ​ | $ | (4,989) | ​ | $ | (21,126) | ​ | $ | (6,812) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | Life Sciences Products | ​ | ​ | Life Sciences Services | ​ | ​ | Total | ​
March 31, 2023 | ​ | ​ | ​ | ​ | ​ | $ | 948,580 | ​ | $ | 849,018 | ​ | $ | 1,797,598 | ​
September 30, 2022 | ​ | ​ | ​ | ​ | ​ |  | 378,790 | ​ | ​ | 849,603 | ​ |  | 1,228,393 | ​

​

The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (in thousands):

34

Table of Contents

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, |  | September 30,
​ | ​ | 2023 | ​ | 2022
Segment assets |  | $ | 1,797,598 |  | $ | 1,228,393
Cash and cash equivalents, restricted cash, and marketable securities | ​ |  | 1,451,703 | ​ |  | 2,305,081
Deferred tax assets | ​ |  | 490 | ​ |  | 1,169
Other assets | ​ | ​ | 23 | ​ | ​ | 181,479
Total assets | ​ | $ | 3,249,814 | ​ | $ | 3,716,122

​

Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three and six months ended March 31, 2023 and 2022 (in thousands) are as follows:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended March 31, | ​ | ​ | Six Months Ended March 31, | ​ | ​
​ |  | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​ | ​
Geographic Location: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
North America | ​ | $ | 87,484 | ​ | $ | 94,283 | ​ | $ | 176,419 | ​ | $ | 184,366 | ​ | ​
Rest of Europe | ​ | ​ | 21,432 | ​ | ​ | 19,745 | ​ | ​ | 60,854 | ​ | ​ | 40,028 | ​ | ​
Africa | ​ | ​ | 8,627 | ​ | ​ | 672 | ​ | ​ | 25,837 | ​ | ​ | 1,219 | ​ | ​
China | ​ | ​ | 11,979 | ​ | ​ | 13,757 | ​ | ​ | 25,387 | ​ | ​ | 26,798 | ​ | ​
Asia Pacific/ Other | ​ | ​ | 13,090 | ​ | ​ | 10,278 | ​ | ​ | 27,068 | ​ | ​ | 17,664 | ​ | ​
United Kingdom | ​ | ​ | 5,789 | ​ | ​ | 6,809 | ​ | ​ | 11,202 | ​ | ​ | 15,121 | ​ | ​
Total | ​ | $ | 148,401 | ​ | $ | 145,544 | ​ | $ | 326,767 | ​ | $ | 285,196 | ​ | ​

​

Revenue for the United States comprises 99% of the revenue for North America for each of the three and six months ended March 31, 2023 and 2022.

​

15. Significant Customers

The Company had no individual customer that accounted for 10% or more of its consolidated revenue for the three months ended March 31, 2022 and 2023. The Company had one individual customer that accounted for 10% or more of its consolidated revenue for six months ended March 31, 2023 and no significant customers that accounted for 10% or more of its consolidated revenue for the six months ended March 31, 2022. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of March 31, 2023 and September 30, 2022.

​

16. Commitments and Contingencies

Tariff Matter

In fiscal year 2021, as part of the Company’s continued integration of GENEWIZ, which was acquired in November 2018, the Company initiated a review during the first quarter of fiscal year 2021, with the assistance of a third party consultant, of the transaction value that the Company has used to calculate tariffs on inter-company imports of samples shipped from its GENEWIZ business. As a result of the third-party review and in light of a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed as a result and recorded a liability of $6.1 million in the second quarter of fiscal 2021. The Company submitted a payment in the amount of $5.9 million to the customs authorities during 2022, related to November 2021 and prior periods. The customs authorities will review the Company’s calculation of tariffs for these periods and determine if any further tariffs are owed. The Company does not expect to incur any significant penalties associated with the tariffs.

Purchase Commitments

35

Table of Contents

At March 31, 2023, the Company had non-cancellable commitments of $83.5 million, comprised of purchase orders for inventory of $56.3 million and information technology related commitments of $27.2 million.

Contingencies

The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. In the third quarter of fiscal year 2020, Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory. In addition, in January 2023, Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for approximately $1.0 million and other related damages, including interest and attorney’s fees, arising from a third-party claim that was included as part of their initial claims. The Company cannot determine the probability of any losses or outcome of these claims including the amount of any indemnifiable losses, if any, resulting from these claims at this time, however, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. In the fiscal quarter ended March 31, 2023, the Company accrued a liability of $2.5 million, equal to the amount of the indemnification escrow as part of the loss on divestiture referred to in Note 3 “Discontinued Operations”. If the resolution of these claims results in indemnifiable losses in excess of the applicable indemnification deductibles and indemnification escrow established under the definitive agreement, Edwards would be required to seek recovery under the representation and warranty insurance Edwards obtained in connection with the closing of the transaction. The Company believes that any indemnifiable losses in excess of the applicable deductibles and indemnification escrow established in the definitive agreement would be covered by such insurance. For indemnifiable claims other than those arising from breaches of representations and warranties and for indemnifiable claims arising from breaches of representations and warranties exceeding the maximum coverage of the representations and warranties insurance policy, Edwards could seek recovery of such indemnifiable losses, if any, directly from the Company. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods.

​

​

17. Fair Value Measurement

The fair value measurement guidance establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value:

​

Level 1 Inputs: Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 Inputs: Observable inputs other than prices included in Level 1, including quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Inputs: Unobservable inputs that are significant to the fair value of the assets or liabilities and reflect an entity’s own assumptions in pricing assets or liabilities since they are supported by little or no market activity.

36

Table of Contents

The Company measures certain assets, including the cost and equity method investments, at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. An impairment charge is recorded when the cost of the investment exceeds its fair value and this condition is determined to be other-than-temporary.

​

37

Table of Contents

​

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the accompanying Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Fair Value Measurements at Reporting Date Using
​ |  | ​ | ​ |  | Quoted Prices in |  | ​ | ​ |  | Significant
​ | ​ | ​ | ​ | ​ | Active Markets for | ​ | Significant Other | ​ | Unobservable
​ | ​ | March 31, | ​ | Identical Assets | ​ | Observable Inputs | ​ | Inputs
Description | ​ | 2023 | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Assets: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Cash equivalents | ​ | $ | 510,643 | ​ | $ | 499,283 | ​ | $ | 11,360 | ​ | $ | —
Available-for-sale securities | ​ |  | 779,827 | ​ |  | 208,527 | ​ | ​ | 571,300 | ​ |  | —
Foreign exchange contracts | ​ |  | 150 | ​ |  | — | ​ |  | 150 | ​ |  | —
Net investment hedge | ​ |  | 1,278 | ​ |  | — | ​ |  | 1,278 | ​ |  | —
Total assets | ​ | $ | 1,291,898 | ​ | $ | 707,810 | ​ | $ | 584,088 | ​ | $ | —
Liabilities: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Contingent consideration liability | ​ | $ | 1,406 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,406
Foreign exchange contracts | ​ | ​ | 164 | ​ | ​ | — | ​ | ​ | 164 | ​ | ​ | —
Total liabilities | ​ | $ | 1,570 | ​ | $ | — | ​ | $ | 164 | ​ | $ | 1,406

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Fair Value Measurements at Reporting Date Using
​ |  | ​ | ​ |  | Quoted Prices in |  | ​ | ​ |  | Significant
​ | ​ | ​ | ​ | ​ | Active Markets for | ​ | Significant Other | ​ | Unobservable
​ | ​ | September 30, | ​ | Identical Assets | ​ | Observable Inputs | ​ | Inputs
Description | ​ | 2022 | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Assets: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Cash equivalents | ​ | $ | 374,804 | ​ | $ | 374,055 | ​ | $ | 749 | ​ | $ | —
Available-for-sale securities | ​ |  | 1,263,782 | ​ |  | 651,800 | ​ |  | 611,982 | ​ |  | —
Foreign exchange contracts | ​ |  | 634 | ​ |  | — | ​ |  | 634 | ​ |  | —
Net investment hedge | ​ | ​ | 124,789 | ​ | ​ | — | ​ | ​ | 124,789 | ​ | ​ | —
Total assets | ​ | $ | 1,764,009 | ​ | $ | 1,025,855 | ​ | $ | 738,154 | ​ | $ | —
Liabilities: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Foreign exchange contracts | ​ | $ | 230 | ​ | $ | — | ​ | $ | 230 | ​ | $ | —
Total liabilities | ​ | $ | 230 | ​ | $ | — | ​ | $ | 230 | ​ | $ | —

​

Cash Equivalents

Cash equivalents consist of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The Company considers all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values.

Available-For-Sale Securities

Available-for-sale securities primarily consist of municipal securities and U.S. government-backed securities, and as such are classified as Level 1. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing and benchmarking because they are not actively traded and bank certificate of deposits. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices.

38

Table of Contents

Foreign Exchange Contracts

Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts.

Net Investment Hedge

Net investment hedge assets are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts.

Contingent Consideration Liability

Contingent consideration liability related to acquisitions is measured and reported at fair value using the real options method based on the unobservable inputs that are significant to the fair value and classified with Level 3 of the fair value hierarchy. The amount is contingent based on the acquired business’ performance for a one-year period from October 3, 2022 through September 30, 2023. Please refer to Note 5, “Business Combinations” for further detail. Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. This liability was revalued from $18.5 million as of December 31, 2022 to $1.4 million as of March 31, 2023 with the offset recorded in the income statement.

Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

During the three and six months ended March 31, 2023 and 2022, the Company did not record any material other-than-temporary impairments on financial assets required to be measured at fair value on a nonrecurring basis.

​

​

18. Subsequent Event

​

As part of the $1.5 billion share repurchase authorization, the Company entered into the ASR Agreement for the repurchase of up to $500 million shares of its common stock on November 23, 2022. On April 3, 2023, the transactions under the ASR Agreement terminated, and on April 5, 2023, the Company received final settlement of an additional 4 million shares of common stock from the Dealer for a total of approximately 10 million shares of common stock repurchased under the ASR Agreement.

​

Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which the Company expect to repurchase up to an additional $500 million shares of its common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

​

​

​

39

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, describes principal factors affecting the results of our operations, financial condition and liquidity as well as our critical accounting policies and estimates that require significant judgment and thus have the most significant potential impact on our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Our MD&A is organized as follows:

| ● | Overview. This section provides a general description of our business and operating segments as well as a brief discussion and overall analysis of our business and financial performance, including key developments affecting the Company during the three and six months ended March 31, 2023 and 2022.

| ● | Critical Accounting Policies and Estimates. This section discusses accounting policies and estimates that require us to exercise subjective or complex judgments in their application. We believe these accounting policies and estimates are important to understanding the assumptions and judgments incorporated in our reported financial results.

| ● | Results of Operations. This section provides an analysis of our financial results for the three and six months ended March 31, 2023 as compared to the three and six months ended March 31, 2022.

| ● | Liquidity and Capital Resources. This section provides an analysis of our liquidity and changes in cash flows as well as a discussion of contractual commitments.

You should read the MD&A in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto and the related MD&A contained in our Annual Report on Form 10-K for the year ended September 30, 2022, filed with the U.S. Securities and Exchange Commission, or the SEC, on November 25, 2022, or the 2022 Annual Report on Form 10-K. In addition to historical information, the MD&A contains forward-looking statements that involve risks and uncertainties. You should read “Information Related to Forward-Looking Statements” below for a discussion of important factors that could cause our actual results to differ materially from our expectations.

​

Impact of the COVID-19 Pandemic

We have implemented business continuity plans designed to address the COVID-19 pandemic and minimize the disruption to ongoing operations. The COVID-19 pandemic has had varying impacts on our financial results. In the first two years of the pandemic, any marginal adverse impact was more than offset by incremental orders related to virus research, COVID testing and vaccine development and commercialization in 2021 and through the first half of 2022. There has been limited COVID-related demand after the second fiscal quarter of 2022, and therefore, our revenue trends since then have been negatively impacted when compared to prior periods. During the third quarter ended June 30, 2022, we experienced a two-week facility closure in Suzhou, China that was required by local government protocols and mandates. We will continue monitoring and assessing the effects of the COVID-19 pandemic on our business, including as a result of the elimination of COVID-related restrictions in China. Our future financial results may be impacted by the pandemic, the extent of which will depend on variables including reduced demand from our customers, the degree that the supply chain may be constrained which could impact our delivery of products and services and the potential negative impact on our operations if there is an outbreak among our employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats.

​

Information Related to Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements that are, or may be considered to be, forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements that are not historical facts, including statements about our beliefs or expectations, are forward-looking statements. These statements may be identified by such forward-looking terminology as “expect,” “estimate,” “intend,” “believe,” “anticipate,” “may,” “will,” “should,” “could,” “continue,” “likely” or similar statements

40

Table of Contents

or variations of such terms. Forward-looking statements include, but are not limited to, statements that relate to our future revenue, margins, costs, earnings, profitability, product development, demand, acceptance and market share, competitiveness, market opportunities and performance, levels of research and development, the success of our marketing, sales and service efforts, outsourced activities, operating expenses, anticipated manufacturing, customer and technical requirements, the ongoing viability of the solutions that we offer and our customers’ success, tax expenses, our management’s plans and objectives for our current and future operations and business focus, our share repurchase program, litigation, our ability to retain, hire and integrate skilled personnel, the impact of the COVID-19 pandemic on our operations and results, our ability to identify and address increased cybersecurity risks, including as a result of employees working remotely, the anticipated growth prospects of our business, the expected benefits and other statements relating to our divestitures and acquisitions, including sale of the semiconductor automation business and the semiconductor cryogenics business, the adequacy, effectiveness and success of our business transformation initiatives, our ability to continue to identify acquisition targets and successfully acquire and integrate desirable products and services and realize expected revenues and revenue synergies, our adoption of newly issued accounting guidance, the levels of customer spending, our dependence on key suppliers or vendors to obtain services for our business on acceptable terms, including the impact of supply chain disruptions, general economic conditions, the sufficiency of financial resources to support future operations, and capital expenditures. Such statements are based on current expectations and involve risks, uncertainties and other factors which may cause the actual results, our performance or our achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include the Risk Factors which are set forth in the 2022 Annual Report on Form 10-K, as updated and/or supplemented in subsequent filings with the SEC, including under Item 1A “Risk Factors” in Part II of our Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on information currently and reasonably known to us. We do not undertake any obligation to release revisions to these forward-looking statements to reflect events or circumstances that occur after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence or effect of anticipated or unanticipated events. Precautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. Any additional precautionary statements made in our 2022 Annual Report on Form 10-K should be read as being applicable to all related forward-looking statements whenever they appear in this Quarterly Report on Form 10-Q.

Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to “we”, “us”, “our” and “the Company” refer to Azenta, Inc. and its consolidated subsidiaries.

OVERVIEW

We are a leading global provider of life sciences sample exploration and management solutions for the life sciences market. We entered the life sciences market in 2011, leveraging our in-house capabilities of precision automation and cryogenics capabilities that we were then applying in the semiconductor market. These led us to provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal development investments and through a series of acquisitions. We now support our customers from research to clinical development with our sample management, automated storage, and genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples including procurement and sourcing, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, and sample repository solutions. Our expertise, global footprint and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology, and life sciences research institutions. In total, we employ approximately 3,600 full-time employees, part-time employees and contingent workers worldwide as of March 31, 2023 and have sales in over 150 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia, and Europe.

Our portfolio includes products and services offerings developed by us internally as well as many offerings we have added through multiple acquisitions designed to bring together a comprehensive capability to service our customers’ needs in the sample-based services arena. We continue to develop new products and services offerings and enhance existing and acquired offerings through the expertise of our research and development resources. We believe our acquisition, investment, and integration approach has allowed us to accelerate internal development and significantly accelerate time to market.

41

Table of Contents

Within our Life Sciences Products segment, we have developed and continue to develop automated biological sample storage solutions for operating in low temperature environments. We have a complete line up of automated stores from ambient temperatures to -190°C. Our BioStore’s ™ unique design allows controlled temperature storage down to -80°C with the industry’s highest throughput of sample retrieval. On October 3, 2022, we acquired B Medical Systems S.á r.l and its subsidiaries, or B Medical, a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. This acquisition complements our cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. Additionally, on February 2, 2023, we acquired Ziath Ltd., a leading provider of 2D barcode readers for life sciences applications to complement our product offerings.

Within our Life Sciences Services segment, our genomics services business advances research and development activities by gene sequencing, synthesis, editing and related services. We offer a comprehensive, global portfolio that we believe has both broad appeal in the life sciences industry and enables customers to select the best solution for their research challenges. This portfolio also offers unique solutions for key markets such as cell and gene therapy, antibody development, and biomarker discovery by addressing genomic complexity and throughput challenges. Our sample repository solutions business is a global leader in sample storage and management and provides a full suite of reliable cold and ultra-cold chain solutions.

​

Sale of the Semiconductor Automation Business

In the fourth quarter of fiscal year 2021, we entered into a definitive agreement to sell our semiconductor automation business to Thomas H. Lee Partners, L.P., or THL, and completed the sale on February 1, 2022, for $2.9 billion in cash. In connection with the planned divestiture of the semiconductor automation business and our continued focus on our life sciences businesses, we changed our corporate name from “Brooks Automation, Inc.” to “Azenta, Inc.” and our common stock started to trade on the Nasdaq Global Select Market under the symbol “AZTA” on December 1, 2021.

Since our founding in 1978, we had been a leading automation provider and partner to the global semiconductor manufacturing industry. With the completion of the sale of the semiconductor automation business, we no longer serve the semiconductor market. The semiconductor automation business has been classified as a discontinued operation and, unless otherwise noted, this MD&A relates solely to our continuing operations and does not include the operations of our semiconductor automation business.

​

​

42

Table of Contents

​

Business and Financial Performance

Our performance for the three and six months ended March 31, 2023 and 2022 are as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​
Dollars in thousands | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​
Revenue | ​ | $ | 148,401 | ​ | $ | 145,544 | ​ | $ | 326,767 | ​ | $ | 285,196 | ​
Cost of revenue | ​ |  | 95,165 | ​ |  | 74,719 | ​ |  | 199,666 | ​ |  | 147,327 | ​
Gross profit | ​ |  | 53,236 | ​ |  | 70,825 | ​ |  | 127,101 | ​ |  | 137,869 | ​
Operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ |  | 8,520 | ​ |  | 6,896 | ​ |  | 16,056 | ​ |  | 13,381 | ​
Selling, general and administrative | ​ |  | 73,339 | ​ |  | 67,915 | ​ |  | 165,891 | ​ |  | 128,626 | ​
Contingent consideration - fair value adjustments | ​ | ​ | (17,145) | ​ | ​ | 600 | ​ | ​ | (17,145) | ​ | ​ | 600 | ​
Restructuring charges | ​ |  | 1,499 | ​ |  | 122 | ​ |  | 2,961 | ​ |  | 295 | ​
Total operating expenses | ​ |  | 66,213 | ​ |  | 75,533 | ​ |  | 167,763 | ​ |  | 142,902 | ​
Operating loss | ​ |  | (12,977) | ​ |  | (4,708) | ​ |  | (40,662) | ​ |  | (5,033) | ​
Interest income | ​ |  | 10,394 | ​ |  | 3,076 | ​ |  | 21,059 | ​ |  | 3,111 | ​
Interest expense | ​ |  | — | ​ |  | (1,555) | ​ |  | — | ​ |  | (2,010) | ​
Loss on extinguishment of debt | ​ | ​ | — | ​ | ​ | (632) | ​ | ​ | — | ​ | ​ | (632) | ​
Other expense, net | ​ |  | (2,668) | ​ |  | (1,170) | ​ |  | (1,523) | ​ |  | (2,248) | ​
Loss before income taxes | ​ |  | (5,251) | ​ |  | (4,989) | ​ |  | (21,126) | ​ |  | (6,812) | ​
Income tax benefit | ​ |  | (3,260) | ​ |  | (3,173) | ​ |  | (7,900) | ​ |  | (7,853) | ​
Income (loss) from continuing operations | ​ | $ | (1,991) | ​ | $ | (1,816) | ​ | $ | (13,226) | ​ | $ | 1,041 | ​
Income (loss) from discontinued operations, net of tax | ​ |  | (2,936) | ​ |  | 2,121,690 | ​ |  | (2,936) | ​ |  | 2,162,152 | ​
Net income (loss) | ​ | $ | (4,927) | ​ | $ | 2,119,874 | ​ | $ | (16,162) | ​ | $ | 2,163,193 | ​

​

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

Results of Operations – Revenue for the three months ended March 31, 2023 increased 2% as compared to the corresponding prior fiscal year period driven by a 10% increase in our Life Sciences Products segment, primarily due to the acquisition of B Medical and Barkey which was offset by the decline in COVID-related revenues in our consumables and instruments business. Gross margin was 35.9% for the three months ended March 31, 2023 as compared to 48.7% for the corresponding period of the prior fiscal year, primarily due to higher costs in both of our segments and unfavorable mix in the Life Sciences Products segment. Operating expenses decreased $9.3 million during the three months ended March 31, 2023 compared to the three months ended March 31, 2022. An increase in selling, general and administrative expenses of $5.4 million during the three months ended March 31, 2023 was offset by a reduction in the fair value of contingent consideration related to B Medical of $17.1 million. We reported an operating loss of $13.0 million for the three months ended March 31, 2023 as compared to an operating loss of $4.7 million for the corresponding prior fiscal year period mainly due to the reduction in gross margin. Loss from continuing operations was $2.0 million for the three months ended March 31, 2023, as compared to a loss of $1.8 million for the three months ended March 31, 2022. During the three months ended March 31, 2023, we recorded a $2.9 million net loss from discontinued operations as compared to net income of $2.1 billion for the three months ended March 31, 2022, primarily due to the accrual of a liability related to a prior disposition, of $2.5 million in the current period.

​

Six Months Ended March 31, 2023 Compared to Six Months Ended March 31, 2022

Results of Operations – Revenue for the six months ended March 31, 2023 increased 15% as compared to the corresponding prior fiscal year period driven by a 44% increase in our Life Sciences Products segment primarily due to the acquisition of B Medical and Barkey which was offset by the decline in COVID-related revenues in our consumables business. Gross margin was 38.9% for the six months ended March 31, 2023 as compared to 48.3% for the corresponding period of the prior fiscal year, primarily due to higher costs in both our segments and unfavorable mix in the Life Sciences Products segment. Operating expenses increased $24.9 million during the six months ended March 31,

43

Table of Contents

2023 compared to the six months ended March 31, 2022. An increase in selling, general and administrative expenses of $37.3 million during the six months ended March 31, 2023 and additional expenses due to the addition of B Medical were partially offset by a reduction in the fair value of the contingent consideration related to B Medical of $17.1 million. We reported an operating loss of $40.7 million and $5.0 million for the six months ended March 31, 2023 and 2022, respectively, mainly due to the reduction in gross margin. Loss from continuing operations was $13.2 million for the six months ended March 31, 2023 as compared to a gain of $1.0 million for the six months ended March 31, 2022. During the six months ended March 31, 2023 we recorded a $2.9 million net loss from discontinued operations as compared to net income of $2.2 billion for the six months ended March 31, 2022, primarily due to the accrual of a liability related to a prior disposition of $2.5 million in the current period.

​

March 31, 2023 Compared to September 30, 2022

Cash Flows and Liquidity - Cash and cash equivalents and restricted cash as presented on our Consolidated Statements of Cash Flows is on a total company basis and were $1.5 billion as of March 31, 2023 compared to $2.3 billion as of September 30, 2022. The decrease of $853.4 million was attributable primarily to outflows of $387.7 million related to the purchase of B Medical and Ziath and $500 million related to the accelerated share repurchase agreement we entered into in November 2022. Cash outflows for operating activities for the six months ended March 31, 2023 were $39.2 million, primarily due to payment of retention bonuses and cash settled stock-based awards, and payment of state taxes for gain on the sale of the semiconductor automation business. Investing inflows of $114.5 million include $728.2 million of sales and maturities of marketable securities, offset by $21.7 million for capital expenditures and $387.7 million paid for the acquisition of B Medical and Ziath. Financing activities for the six months ended March 31, 2023 include the outflows related to the accelerated share repurchase agreement. The effects of foreign exchange rate fluctuations reduced our cash balance by $60.4 million as of March 31, 2023.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our unaudited consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles, or GAAP. The preparation of the interim consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue, intangible assets, goodwill, inventories, income taxes, and stock-based compensation. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate current and anticipated worldwide economic conditions, both in general and specifically in relation to the life science industry, that serve as a basis for making judgments about the carrying values of assets and liabilities that are not readily determinable based on information from other sources. Actual results may differ from these estimates under different assumptions or conditions that could have a material impact on our financial condition and results of operations.

For further information with regard to our significant accounting policies and estimates, please refer to Note 2, "Summary of Significant Accounting Policies" in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q and in the Notes to our audited consolidated financial statements included in Part II, Item 8 “Financial Statements and Supplementary Data” in our 2022 Annual Report on Form 10-K.

Recently Issued and Adopted Accounting Pronouncements

For a summary of recently issued and adopted accounting pronouncements applicable to our unaudited consolidated financial statements, please refer to Note 2, "Summary of Significant Accounting Policies" in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q.

44

Table of Contents

RESULTS OF OPERATIONS

Please refer to the commentary provided below for further discussion and analysis of the factors contributing to our results from operations for the three and six months ended March 31, 2023 as compared to the three and six months ended March 31, 2022.

​

45

Table of Contents

Revenue

Our revenue performance for the three and six months ended March 31, 2023 and 2022 is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | ​ | ​ | Six Months Ended March 31, | ​
Dollars in thousands | ​ | 2023 | ​ | ​ | 2022 | ​ | % Change | ​ | ​ | ​ | 2023 | ​ | ​ | 2022 | ​ | % Change | ​
Life Sciences Products | ​ | $ | 58,860 | ​ | ​ | $ | 53,615 | ​ | 10 | % | ​ | ​ | ​ | $ | 148,520 | ​ | ​ | $ | 103,487 | ​ | 44 | % | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Services | ​ | $ | 89,541 | ​ | ​ | $ | 91,929 | ​ | (3) | % | ​ | ​ | ​ | $ | 178,247 | ​ | ​ | $ | 181,709 | ​ | (2) | % | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total revenue | ​ | $ | 148,401 | ​ | ​ | $ | 145,544 | ​ | 2 | % | ​ | ​ | ​ | $ | 326,767 | ​ | ​ | $ | 285,196 | ​ | 15 | % | ​

​

Three months ended March 31, 2023 compared to three months ended March 31, 2022

Revenue for the three months ended March 31, 2023 increased 2% as compared to the corresponding prior fiscal year period, driven by a 10% increase in our Life Sciences Products segment slightly offset by a 3% decline in our Life Sciences Services segment.

Our Life Sciences Products segment revenue for the three months ended March 31, 2023 increased 10% as compared to the corresponding prior fiscal year period driven by the acquisitions of B Medical and Barkey. Excluding the acquisitions, we experienced decreased demand and associated revenue for COVID-19 related consumables and instruments; which was partially offset by increased revenue in our automated cold sample management systems.

Our Life Sciences Services segment revenue for the three months ended March 31, 2023 decreased 3% as compared to the corresponding prior fiscal year period driven by a 4% year-over-year decrease in our genomics business; mainly from lower synthesis revenue.

We estimate that revenue related to the COVID-19 pandemic for the three months ended March 31, 2023 was approximately $3 million in the aggregate, including $2 million from B Medical, as compared to COVID-19-related revenue of approximately $10 million for the three months ended March 31, 2022. The decrease in this revenue was primarily due to lower demand for consumables related to COVID-19 testing.

Revenue generated outside the United States was $61.8 million, or 42% of total revenue, for the three months ended March 31, 2023 as compared to $52.0 million, or 36% of total revenue, for the corresponding period of the prior fiscal year, primarily due to the addition of B Medical. There were no customers with more than 10% of our consolidated revenue for the three months ended March 31, 2023.

Six months ended March 31, 2023 compared to six months ended March 31, 2022

Revenue for the six months ended March 31, 2023 increased 15% as compared to the corresponding prior fiscal year period, driven by a 44% increase in our Life Sciences Products segment slightly offset by a 2% decline in our Life Sciences Services segment.

Our Life Sciences Products segment revenue for the six months ended March 31, 2023 increased 44% as compared to the corresponding prior fiscal year period driven by the acquisitions of B Medical and Barkey. Excluding the acquisitions, we experienced decreased demand and associated revenue for COVID-19 related consumables and instruments; which was partially offset by increased revenue in our automated cold sample management systems.

Our Life Sciences Services segment revenue for the six months ended March 31, 2023 decreased 2% as compared to the corresponding prior fiscal year period driven by lower synthesis revenue in our Genomics business.

We estimate that revenue related to the COVID-19 pandemic for the six months ended March 31, 2023 was approximately $4 million in the aggregate, including $3 million from B Medical, as compared to COVID-19-related

46

Table of Contents

revenue of approximately $20 million for the six months ended March 31, 2022. The decrease in this revenue was primarily due to lower demand for consumables related to COVID-19 testing.

Revenue generated outside the United States was $152.5 million, or 47% of total revenue, for the six months ended March 31, 2023 as compared to $102.1 million, or 36% of total revenue, for the corresponding period of the prior fiscal year, primarily due to the addition of B Medical. There was one customer with more than 10% of the Company’s consolidated revenue for the six months ended March 31, 2023. This individual customer is a distributor shipping to end users in 17 countries.

Operating Income (Loss)

Our operating income (loss) performance for the three and six months ended March 31, 2023 and 2022 is as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Three Months Ended March 31, | ​ | Six Months Ended March 31,
Dollars in thousands | 2023 | ​ | 2022 | ​ | ​ | 2023 | ​ | 2022 | ​
Revenue: | ​ |  |  | ​ |  |  | ​ | ​ |  |  | ​ |  |
Life Sciences Products | $ | 58,860 | ​ | $ | 53,615 | ​ | ​ | $ | 148,520 | ​ | $ | 103,487 | ​
Life Sciences Services |  | 89,541 | ​ |  | 91,929 | ​ | ​ |  | 178,247 | ​ |  | 181,709 | ​
Total revenue | $ | 148,401 | ​ | $ | 145,544 | ​ | ​ | $ | 326,767 | ​ | $ | 285,196 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (loss): |  | ​ | ​ |  | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​
Life Sciences Products adjusted | $ | (9,819) | ​ | $ | 5,288 | ​ | ​ | $ | (6,489) | ​ | $ | 9,679 | ​
Life Sciences Products adjusted operating margin | ​ | (17) | % | ​ | 10 | % | ​ | ​ | (4) | % | ​ | 9 | %
Amortization of completed technology | ​ | (3,569) | ​ | ​ | (267) | ​ | ​ | ​ | (6,414) | ​ | ​ | (471) | ​
Purchase accounting impact on inventory | ​ | (2,912) | ​ | ​ | — | ​ | ​ | ​ | (5,781) | ​ | ​ | — | ​
Other unallocated corporate expenses | ​ | (102) | ​ | ​ | — | ​ | ​ | ​ | (1,515) | ​ | ​ | — | ​
Total Life Sciences Products operating income (loss) | ​ | (16,402) | ​ | ​ | 5,021 | ​ | ​ | ​ | (20,199) | ​ | ​ | 9,208 | ​
Life Sciences Products operating margin | ​ | (28) | % | ​ | 9 | % | ​ | ​ | (14) | % | ​ | 9 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Services adjusted | $ | (3,435) | ​ | $ | 4,856 | ​ | ​ | $ | (6,724) | ​ | $ | 12,740 | ​
Life Sciences Services adjusted operating margin | ​ | (4) | % | ​ | 5 | % | ​ | ​ | (4) | % | ​ | 7 | %
Amortization of completed technology | ​ | (1,333) | ​ | ​ | (1,572) | ​ | ​ | ​ | (2,655) | ​ | ​ | (3,142) | ​
Tariff adjustment | ​ | — | ​ | ​ | 486 | ​ | ​ | ​ | — | ​ | ​ | 486 | ​
Other unallocated corporate expenses | ​ | (110) | ​ | ​ | — | ​ | ​ | ​ | (110) | ​ | ​ | (13) | ​
Total Life Sciences Services operating income (loss) | ​ | (4,878) | ​ | ​ | 3,770 | ​ | ​ | ​ | (9,489) | ​ | ​ | 10,071 | ​
Life Sciences Services operating margin | ​ | (5) | % | ​ | 4 | % | ​ | ​ | (5) | % | ​ | 6 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating income (loss) | $ | (21,280) | ​ | $ | 8,791 | ​ | ​ | $ | (29,688) | ​ | $ | 19,279 | ​
Total segment operating margin | ​ | (14) | % | ​ | 6 | % | ​ | ​ | (9) | % | ​ | 7 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Corporate adjusted | ​ | (18) | ​ | ​ | (444) | ​ | ​ | ​ | (99) | ​ | ​ | (473) | ​
Amortization of customer relationships and acquired intangible assets | ​ | 7,407 | ​ | ​ | 6,047 | ​ | ​ | ​ | 14,882 | ​ | ​ | 12,319 | ​
Rebranding and transformation costs | ​ | 10 | ​ | ​ | 1,297 | ​ | ​ | ​ | (55) | ​ | ​ | 1,916 | ​
Restructuring charges | ​ | 1,389 | ​ | ​ | 122 | ​ | ​ | ​ | 2,960 | ​ | ​ | 296 | ​
Contingent consideration - fair value adjustments | ​ | (17,145) | ​ | ​ | 600 | ​ | ​ | ​ | (17,145) | ​ | ​ | 600 | ​
Merger and acquisition costs and costs related to share repurchase | ​ | (211) | ​ | ​ | 4,989 | ​ | ​ | ​ | 10,232 | ​ | ​ | 8,708 | ​
Other adjustment | ​ | 230 | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ | — | ​
Corporate operating income (loss) | $ | 8,302 | ​ | $ | (13,499) | ​ | ​ | $ | (10,973) | ​ | $ | (24,312) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total operating income (loss) | $ | (12,977) | ​ | $ | (4,708) | ​ | ​ | $ | (40,662) | ​ | $ | (5,033) | ​
Total operating margin | ​ | (9) | % | ​ | (3) | % | ​ | ​ | (12) | % | ​ | (2) | %

​

Three months ended March 31, 2023 compared to three months ended March 31, 2022

​

We reported an operating loss of $13.0 million during the three month period ending March 31, 2023 compared to an operating loss of $4.7 million in the prior fiscal year period. The increase in operating loss was due to lower gross margin in both of our segments of $17.6 million, partially offset by lower operating expense of $9.3 million. Within operating expenses, research and development expenses increased $1.6 million and selling, general, and administrative expenses increased $5.4 million. Selling, general and administrative expenses increased due to continued investment in

47

Table of Contents

the business to build out the commercial and laboratory support infrastructure. These increased expenses were partially offset by an reduction in the carrying value of contingent consideration related to B Medical of $17.1 million.

Life Sciences Products segment adjusted operating income decreased $15.1 million and adjusted operating margin decreased 26.5 percentage points for the three months ended March 31, 2023 compared to the corresponding prior fiscal year period. The decrease in adjusted operating income was driven by lower adjusted gross margin of $5.8 million and an increase in adjusted operating expenses of $9.3 million (primarily due to the addition of B Medical). Adjusted operating income for our Life Sciences Products segment excludes charges for amortization related to completed technology of $3.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively, and $2.9 million purchase accounting impact on inventory for the three months ended March 31, 2023. Please refer to Note 14, “Segment and Geographic Information” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q.

Life Sciences Services segment adjusted operating income decreased $8.3 million and adjusted operating margin decreased 9.1 percentage points for the three months ended March 31, 2023 compared to the corresponding prior fiscal year period. The decrease in adjusted operating margin was driven by lower adjusted gross margin of $5.3 million and higher adjusted operating expenses of $3.0 million. Adjusted operating income for our Life Sciences Services segment excludes charges for amortization related to completed technology of $1.3 million and $1.6 million for the three months ended March 31, 2023 and 2022, respectively. Please refer to Note 14, “Segment and Geographic Information” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q.

​

Six months ended March 31, 2023 compared to six months ended March 31, 2022

​

We reported an operating loss of $40.7 million during the six month period ending March 31, 2023 compared to an operating loss of $5.0 million in the prior fiscal year period. The increase in operating loss was due to lower gross margin in both of our segments of $10.8 million, and higher operating expenses of $24.9 million. Within operating expenses, research and development expenses increased $2.7 million and selling, general, and administrative expenses increased $37.3 million. Selling, general and administrative expenses increased due to the addition of B Medical and continued investment in the business to build out the commercial and laboratory support infrastructure. These increased expenses were partially offset by an adjustment to the fair value of contingent consideration related to B Medical of $17.1 million.

Life Sciences Products segment adjusted operating income decreased $16.1 million and adjusted operating margin decreased 13.7 percentage points for the six months ended March 31, 2023 compared to the corresponding prior fiscal year period. The decrease in adjusted operating income was driven by an increase in adjusted operating expenses of $26.2 million (primarily due to the addition of B Medical), offset with higher adjusted gross margin from increased revenues of $45.0 million. Adjusted operating income for our Life Sciences Products segment excludes charges for amortization related to completed technology of $6.4 million and $0.5 million for the six months ended March 31, 2023 and 2022, respectively, and $5.8 million purchase accounting impact on inventory for the six months ended March 31, 2023. Please refer to Note 14, “Segment and Geographic Information” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q.

Life Sciences Services segment adjusted operating income decreased $19.5 million and adjusted operating margin decreased 10.8 percentage points for the six months ended March 31, 2023 compared to the corresponding prior fiscal year period. The decrease in adjusted operating margin was driven by lower adjusted gross margin of $9.1 million and higher adjusted operating expenses of $10.4 million. Adjusted operating income for our Life Sciences Services segment excludes charges for amortization related to completed technology of $2.7 and $3.1 million for the six months ended March 31, 2023 and 2022, respectively. Please refer to Note 14, “Segment and Geographic Information” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q.

​

​

48

Table of Contents

Gross Margin

Our gross margin performance for the three and six months ended March 31, 2023 and 2022 is as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Life Science Products | Life Science Services | Azenta Total
​ | ​ | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31,
Dollars in thousands | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022
Revenue | ​ | $ | 58,860 | ​ | ​ | $ | 53,615 | ​ | ​ | $ | 89,541 | ​ | ​ | $ | 91,929 | ​ | ​ | $ | 148,401 | ​ | ​ | $ | 145,544 | ​
Gross profit |  | ​ | 14,284 |  | ​ | ​ | 26,290 |  | ​ | ​ | 38,952 |  | ​ | ​ | 44,535 |  | ​ | ​ | 53,236 |  | ​ | ​ | 70,825 |
Gross margin | ​ | ​ | 24.3 | % | ​ | ​ | 49.0 | % | ​ | ​ | 43.5 | % | ​ | ​ | 48.4 | % | ​ | ​ | 35.9 | % | ​ | ​ | 48.7 | %
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of completed technology | ​ |  | 3,568 | ​ | ​ |  | 267 | ​ | ​ |  | 1,333 | ​ | ​ |  | 1,572 | ​ | ​ |  | 4,901 | ​ | ​ |  | 1,839 | ​
Purchase accounting impact on inventory | ​ | ​ | 2,912 | ​ | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ |  | — | ​ | ​ | ​ | 2,912 | ​ | ​ |  | — | ​
Other unallocated corporate expenses | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ |  | (486) | ​ | ​ | ​ | — | ​ | ​ |  | (486) | ​
Adjusted gross profit | ​ | $ | 20,764 | ​ | ​ | $ | 26,557 | ​ | ​ | $ | 40,285 | ​ | ​ | $ | 45,621 | ​ | ​ | $ | 61,049 | ​ | ​ | $ | 72,178 | ​
Adjusted gross margin | ​ | ​ | 35.3 | % | ​ | ​ | 49.5 | % | ​ | ​ | 45.0 | % | ​ | ​ | 49.6 | % | ​ | ​ | 41.1 | % | ​ | ​ | 49.6 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Life Science Products | Life Science Services | Azenta Total
​ | ​ | Six Months Ended March 31, | Six Months Ended March 31, | Six Months Ended March 31,
Dollars in thousands | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022 | ​ | 2023 | ​ | 2022
Revenue | ​ | $ | 148,520 | ​ | ​ | $ | 103,487 | ​ | ​ | $ | 178,247 | ​ | ​ | $ | 181,709 | ​ | ​ | $ | 326,767 | ​ | ​ | $ | 285,196 | ​
Gross profit |  | ​ | 47,264 |  | ​ | ​ | 48,980 |  | ​ | ​ | 79,837 |  | ​ | ​ | 88,902 |  | ​ | ​ | 127,101 |  | ​ | ​ | 137,869 |
Gross margin | ​ | ​ | 31.8 | % | ​ | ​ | 47.3 | % | ​ | ​ | 44.8 | % | ​ | ​ | 48.9 | % | ​ | ​ | 38.9 | % | ​ | ​ | 48.3 | %
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of completed technology | ​ |  | 6,414 | ​ | ​ |  | 471 | ​ | ​ |  | 2,655 | ​ | ​ |  | 3,142 | ​ | ​ |  | 9,069 | ​ | ​ |  | 3,613 | ​
Purchase accounting impact on inventory | ​ | ​ | 5,781 | ​ | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ |  | — | ​ | ​ | ​ | 5,781 | ​ | ​ |  | — | ​
Tariff adjustment | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ | ​ | — | ​ | ​ |  | (486) | ​ | ​ | ​ | — | ​ | ​ |  | (486) | ​
Adjusted gross profit | ​ | $ | 59,459 | ​ | ​ | $ | 49,451 | ​ | ​ | $ | 82,492 | ​ | ​ | $ | 91,558 | ​ | ​ | $ | 141,951 | ​ | ​ | $ | 140,996 | ​
Adjusted gross margin | ​ | ​ | 40.0 | % | ​ | ​ | 47.8 | % | ​ | ​ | 46.3 | % | ​ | ​ | 50.4 | % | ​ | ​ | 43.4 | % | ​ | ​ | 49.4 | %

​

Three months ended March 31, 2023 compared to three months ended March 31, 2022

​

Gross margin decreased 12.8 percentage points for the three months ended March 31, 2023 to 35.9% compared to the corresponding prior fiscal year period driven by decreased gross margin in both our Life Sciences Products segment and our Life Sciences Services segment.

Life Sciences Products segment gross margin decreased 24.7 percentage points for the three months ended March 31, 2023 as compared to the corresponding fiscal year period. The decrease was primarily driven by the impact of amortization of intangible assets and purchase accounting inventory basis for B Medical, and from higher costs and unfavorable product mix in revenue. Cost of revenue included $3.6 million amortization of completed technology and $2.9 million for purchase accounting impact on inventory for the three months ended March 31, 2023, and $0.3 million of charges for amortization related to completed technology for the three months ended March 31, 2022. Excluding the impact of the amortization of completed technology and purchase accounting impact on inventory, margins decreased 14.2 percentage points during the three months ended March 31, 2023 as compared to the corresponding period of the prior fiscal year, primarily due to the mix of products sold in our consumables and instruments and cryogenic stores businesses, unfavorable cost adjustments in our stores contracts, and lower cost absorption due to lower revenue.

Life Sciences Services segment gross margin decreased 4.9 percentage points driven by decreased gross margin in both the genomic services business and sample repository solutions business. The decrease in the genomic services business was due to the impact of lower sales, higher labor costs and continued investment in the business. The decrease in gross margin in the sample repository solutions business is mainly driven by credit memos issued in the quarter. Cost of revenue included $1.3 million and $1.6 million of charges for amortization related to completed technology for the three months ended March 31, 2023 and 2022, respectively. Excluding the impact of the amortization of completed

49

Table of Contents

technology and other unallocated corporate expenses, Life Sciences Services margins decreased 4.6 percentage points during the three months ended March 31, 2023 as compared to the corresponding period of the prior fiscal year.

​

Six months ended March 31, 2023 compared to six months ended March 31, 2022

​

Total gross margin decreased 9.4 percentage points for the six months ended March 31, 2023 to 38.9% compared to the corresponding prior fiscal year period driven by decreased gross margin in both our Life Sciences Products segment and our Life Sciences Services segment.

Life Sciences Products segment gross margin decreased 15.5 percentage points for the six months ended March 31, 2023, as compared to the corresponding fiscal year period. The decrease was primarily driven by the impact of amortization of intangible assets and purchase accounting inventory basis for B Medical, and from higher costs and unfavorable product mix in revenue. Cost of revenue included $6.4 million amortization of completed technology and $5.8 million for purchase accounting impact on inventory for the six months ended March 31, 2023 and $0.5 million of charges for amortization related to completed technology for the six months ended March 31, 2022. Excluding the impact of the amortization of completed technology and purchase accounting impact on inventory, margins decreased 7.7 percentage points during the six months ended March 31, 2023, as compared to the corresponding period of the prior fiscal year, primarily due to the mix of products sold in our consumables and instruments and cryogenic stores businesses, unfavorable cost adjustments in our stores contracts, and lower cost absorption due to lower revenue.

Life Sciences Services segment gross margin decreased 4.1 percentage points driven by decreased gross margin in both the genomic services business and sample repository solutions business. The decrease in the genomic services business was due to the impact of lower sales, higher labor costs and continued investment in the business. The decrease in gross margin in the sample repository solutions business is mainly driven by credit memos issued in the period. Cost of revenue included $2.7 million and $3.1 million of charges for amortization related to completed technology for the six months ended March 31, 2023, and 2022, respectively. Excluding the impact of the amortization of completed technology and tariff adjustments, Life Sciences Services margins decreased 4.1 percentage points during the six months ended March 31, 2023, as compared to the corresponding period of the prior fiscal year.

​

​

50

Table of Contents

Research and Development Expenses

Our research and development expense for the three and six months ended March 31, 2023 and 2022 is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31,
Dollars in thousands | ​ | 2023 | ​ | ​ | 2022 | ​ | ​ | 2023 | ​ | 2022 | ​
Life Sciences Products | ​ | $ | 5,364 | ​ | ​ | $ | 3,818 | ​ | ​ | $ | 9,732 | ​ | ​ | $ | 7,229 | ​
Percent-Segment Revenue | ​ | ​ | 9.1 | ​ | % | ​ | 7.1 | % | ​ | ​ | 6.6 | % | ​ | ​ | 7.0 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Services | ​ | $ | 3,156 | ​ | ​ | $ | 3,078 | ​ | ​ | $ | 6,323 | ​ | ​ | $ | 6,152 | ​
Percent-Segment Revenue | ​ | ​ | 3.5 | ​ | % | ​ | 3.3 | % | ​ | ​ | 3.5 | % | ​ | ​ | 3.4 | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total research and development expense | ​ | $ | 8,520 | ​ | ​ | $ | 6,896 | ​ | ​ | $ | 16,055 | ​ | ​ | $ | 13,380 | ​
Percent-Total Revenue | ​ | ​ | 5.7 | ​ | % | ​ | 4.7 | % | ​ | ​ | 4.9 | % | ​ | ​ | 4.7 | %

​

Research and development expenses for the three months ended March 31, 2023 increased $1.6 million as compared to the three months ended March 31, 2022, driven by the acquisition of B Medical as well as an increase in product development. Research and development expenses for the six months ended March 31, 2023 increased $2.7 million as compared to the six months ended March 31, 2022, driven by a $2.5 million increase in our Life Sciences Products segment and a $0.2 million increase in our Life Sciences Services segment. The increase for the three and six months ended March 31, 2023 in Life Sciences Products was driven by the addition of B Medical and development of new products.

​

Selling, General and Administrative Expenses

Our selling, general and administrative expenses for the three months ended March 31, 2023 and 2022 is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Six Months Ended March 31, | ​ | ​
Dollars in thousands | ​ | 2023 | ​ | ​ | 2022 | ​ | ​ | 2023 | ​ | 2022 | ​ | ​
Life Sciences Products | ​ | $ | 25,322 | ​ | ​ | $ | 17,451 | ​ | ​ | $ | 57,731 | ​ | ​ | $ | 32,544 | ​ | ​ | ​
Percent-Segment Revenue | ​ | ​ | 43.0 | ​ | % | ​ | 32.5 | % | ​ | ​ | 38.9 | % | ​ | ​ | 31.4 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Life Sciences Services | ​ | $ | 40,673 | ​ | ​ | $ | 37,688 | ​ | ​ | $ | 83,002 | ​ | ​ | $ | 72,666 | ​ | ​ | ​
Percent-Segment Revenue | ​ | ​ | 45.4 | ​ | % | ​ | 41.0 | % | ​ | ​ | 46.6 | % | ​ | ​ | 40.0 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Corporate | ​ | $ | 7,344 | ​ | ​ | $ | 13,376 | ​ | ​ | $ | 25,158 | ​ | ​ | $ | 24,016 | ​ | ​ | ​
Percent-Total Revenue | ​ | ​ | 4.9 | ​ | % | ​ | 9.2 | % | ​ | ​ | 7.7 | % | ​ | ​ | 8.4 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total selling, general and administrative expense | ​ | $ | 73,339 | ​ | ​ | $ | 68,515 | ​ | ​ | $ | 165,891 | ​ | ​ | $ | 128,626 | ​ | ​ | ​
Percent-Total Revenue | ​ | ​ | 49.4 | ​ | % | ​ | 47.1 | % | ​ | ​ | 50.8 | % | ​ | ​ | 45.1 | % | ​ | ​

​

Total selling, general and administrative expenses increased $4.8 million and $37.3 million, respectively, for the three and six months ended March 31, 2023 as compared to the three and six months ended March 31, 2022, driven by higher costs in both our segments.

Within our segment expenses discussed below, we allocate certain corporate general and administrative expenses including costs related to shared corporate functions which include finance, information technology, human resources, legal, executive, governance, logistics and compliance. In total, corporate general and administrative expense allocated to segments decreased $0.4 million for the three months ended March 31, 2023. For the six months ended March 31, 2023, these costs increased $4.0 million as compared to the corresponding period of the prior fiscal year, primarily due to higher labor costs and investment in the commercial organization.

​

Life Sciences Products segment selling, general and administrative expenses increased $7.9 million and $25.2 million, for the three and six months ended March 31, 2023, respectively, as compared to the corresponding prior fiscal year period primarily related to the addition of B Medical. Selling, general and administrative expenses included $0.1 million and $0.0 million of charges for amortization related to customer relationship and trademark assets for the three months ended March 31, 2023 and 2022, respectively. Excluding the impact of the amortization of these assets, selling,

51

Table of Contents

general and administrative expenses increased $7.8 million and $25.2 million for the three and six months ended March 31, 2023, respectively, due to the addition of B Medical and higher labor costs.

Life Sciences Services segment selling, general and administrative expenses increased $3.0 million and $10.3 million for the three and six months ended March 31, 2023, respectively, as compared to the corresponding prior fiscal year period, which increases were related to investments in the commercial organization and laboratory support personnel.

Unallocated corporate expenses decreased $6.0 million and increased $1.1 million for the three and six months ended March 31, 2023, respectively, as compared to the corresponding prior fiscal year period. The three months ended March 31, 2022 included costs related to the semiconductor automation disposition, which did not repeat in the corresponding 2023 period. Unallocated costs increased in the six months ended March 31, 2023 as compared to the corresponding period of the prior fiscal year due to costs and costs related to the accelerated share repurchase agreement we entered into in November 2022.

Restructuring Charges

Restructuring charges increased by $1.4 million and $2.7 million for the three and six months ended March 31, 2023, respectively, as compared to the three and six months ended March 31, 2022. The three and six months ended March 31, 2023 includes restructuring charges related to the separation of personnel. Costs savings from these actions are expected to be realized by the end of June 30, 2023.

Non-Operating Income (Expenses)

Interest income – We recorded interest income of $10.3 million and $21.0 million for the three and six months ended March 31 2023, respectively, as compared to $3.1 million recorded in both the corresponding periods of the prior fiscal year. This increase in interest income is due to interest earned on the proceeds from the sale of the semiconductor automation business, including interest accrued on a net investment hedge, during the three and six month period ended March 31, 2023. Please refer to the Derivative Financial Instruments section of Note 2, “Summary of Significant Accounting Policies” in the Notes to the unaudited consolidated financial statements included in Item 1 “Consolidated Financial Statements” of this Quarterly Report on Form 10-Q.

Interest expense – During the three and six months ended March 31, 2023 we recorded interest expense of $0.0 million and $0.0 million, respectively, as compared to $1.5 million and $2.0 million, respectively, during the corresponding period of the prior fiscal year. The decrease in interest expense for the three and six months ended March 31, 2023, is attributed to our previously outstanding term loan that was settled on February 1, 2022 using the proceeds from the sale of the semiconductor automation business. We incurred a loss on extinguishment of debt of $0.6 million during the three and six months ended March 31, 2022.

Other income (expenses) – We recorded other expense of $2.7 million and $1.5 million for the three and six months ended March 31, 2023, respectively, as compared to other expense of $1.2 million and $2.2 million, respectively, for the three and six months ended March 31, 2022, primarily due to lower foreign exchange losses during the period.

​

Income Tax Provision / Benefit

We recorded an income tax benefit of $3.3 million and $7.9 million, respectively during the three and six months ended March 31, 2023. The tax benefit for the three months ended March 31, 2023 was primarily driven by the pre-tax loss from operations during the period. The tax benefit for the six months ended March 31, 2023 was primarily driven by the pre-tax loss from operations and a $1.4 million deferred tax benefit resulting from the extension of a tax incentive in China. The effective tax rates for the three and six months ended March 31, 2023 are substantially higher than statutory rates. The effective rates are driven higher than the statutory rates by the discrete tax benefit in China noted above and the fair value adjustment of the contingent consideration related to the B Medical acquisition. The contingent consideration generated $17.1 million of pre-tax income that is not subject to income taxes, therefore, the tax benefit is being driven by a tax loss that is significantly higher than the book loss for these periods. The effective

52

Table of Contents

tax rate on a six-month basis without these discrete events is slightly higher than average statutory tax rates due to the jurisdictional mix of income with losses being generated in higher tax jurisdictions and income being generated in lower jurisdictions.

We recorded an income tax benefit of $3.2 million and $7.9 million, respectively during the three and six months ended March 31, 2022. The tax benefit for the three months ended March 31, 2022 was primarily driven by the benefit on loss from operations during the period. The tax benefit for the six months ended March 31, 2022 was increased by a $4.5 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The tax benefit for the six months ended March 31, 2022 was partially offset by a $0.6 million charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets.

The effective tax rates for the three and six months ended March 31, 2022 were significantly higher than the statutory rates, which was driven by the tax benefit on the stock compensation deduction and near break-even pre-tax losses of $1.8 million and $5.0 million, respectively.

Discontinued Operations

There was no revenue from discontinued operations for the three and six months ended March 31, 2023. Revenue from discontinued operations was $60.8 million and $264.4 million for the three and six months ended March 31, 2022, respectively. Net loss from discontinued operation was $2.9 million for both of the three and six months ended March 31, 2023, primarily driven by a liability recorded for potential claims from the sale of the semiconductor cryogenics business in fiscal year 2018. Net Income from discontinued operations was $2.1 billion for both the three and six months ended March 31, 2022, representing the sale of the semiconductor solutions group on February 1, 2022. The income from discontinued operations only includes direct operating expenses incurred that (1) are clearly identifiable as costs being disposed of upon completion of the sale and (2) will not be continued by our company on an ongoing basis. Indirect expenses which supported the semiconductor automation business, and which remained as part of the continuing operations, are not reflected in income from discontinued operations.

LIQUIDITY AND CAPITAL RESOURCES

We believe that we have adequate resources to satisfy our working capital, financing activities, and capital expenditure requirements for the next twelve months. The current global economic environment, including the uncertainty related to the COVID-19 pandemic, make it difficult for us to predict longer-term liquidity requirements with sufficient certainty. We may be unable to obtain any required additional financing on terms favorable to us, if at all. If adequate funds are not available to us on acceptable terms or otherwise, we may be unable to successfully develop or enhance products and services, respond to competitive pressure or take advantage of acquisition opportunities, any of which could have a material adverse effect on our business, financial condition and operating results.

​

The discussion of our cash flows and liquidity that follows stated on a total company consolidated basis and excludes the impact of discontinued operations.

53

Table of Contents

Overview of Cash Flows and Liquidity

Our cash and cash equivalents, restricted cash and marketable securities as of March 31, 2023 and September 30, 2022 consist of the following (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, 2023 |  | September 30, 2022 |
Cash and cash equivalents | ​ | $ | 667,365 | ​ | $ | 658,274 | ​
Restricted cash | ​ | ​ | 4,511 | ​ | ​ | 383,023 | ​
Short-term marketable securities | ​ |  | 513,651 | ​ |  | 911,764 | ​
Long-term marketable securities | ​ |  | 266,176 | ​ |  | 352,020 | ​
​ | ​ | $ | 1,451,703 | ​ | $ | 2,305,081 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

Our cash and cash equivalents, restricted cash and marketable securities were $1.5 billion as of March 31, 2023. As of March 31, 2023, we had cash, cash equivalents and restricted cash of $671.9 million, of which $542.2 million was held outside of the United States. If these funds are needed for the U.S. operations, we would need to repatriate these funds. As a result of changes in U.S. tax legislation, any repatriation in the future would likely not result in U.S. federal income tax. We had marketable securities of $779.8 million and $1.3 billion as of March 31, 2023 and September 30, 2022, respectively. Our marketable securities are generally readily convertible to cash without a material adverse impact.

Cash outflows for operating activities for the six months ended March 31, 2023 were $39.2 million, primarily due to payment of retention bonuses and cash settled stock-based awards, as well as state income taxes for the semiconductor automation business. Investing inflows of $114.5 million include $728.2 million of sales and maturities of marketable securities, offset by $21.7 million for capital expenditures and $387.7 million paid for the acquisition of B Medical. Financing activities for the six months ended March 31, 2023 include $500.0 million of outflows related to the accelerated share repurchase agreement. The effects of foreign exchange rate fluctuations reduced our cash balance by $60.4 million as of March 31, 2023.

54

Table of Contents

Capital Resources

Share Repurchase Program

On September 29, 2015, our Board of Directors approved an authorization to repurchase up to $50 million of our common stock. On November 4, 2022, our Board of Directors terminated the existing share repurchase authorization and approved a new authorization to repurchase of up to $1.5 billion of our common stock, or the 2022 Repurchase Authorization. Repurchases under the 2022 Repurchase Authorization may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase, or ASR, agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market and business conditions, legal requirements, and other factors. We are not obligated to acquire any particular amount of common stock under the 2022 Repurchase Authorization, and share repurchases may be commenced or suspended at any time at our discretion. As part of the 2022 Repurchase Authorization, we entered into an ASR agreement for the repurchase of $500 million of our common stock on November 23, 2022, and received an initial delivery of, and retired, 6.1 million shares of common stock at that time. The ASR agreement terminated on April 3, 2023, and we received and retired an additional 4 million shares of common stock as of that date.

See Note 11, “Stockholders’ Equity” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q for additional information about the ASR agreement.

Following the final termination of the ASR agreement in April 2023, new arrangements commenced under which we expect to repurchase up to an additional $500 million shares of our common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

Contractual Obligations and Requirements

At March 31, 2023, we had non-cancellable commitments of $83.5 million, comprised primarily of purchase orders for inventory of $56.3 million, and information technology related commitments of $27.2 million.

Off-Balance Sheet Arrangements

As of March 31, 2023, we had no obligations, assets or liabilities which would be considered off-balance sheet arrangements.

​

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to a variety of market risks, including changes in interest rates affecting investment return on our cash and cash equivalents, restricted cash and short-term and long-term investments and fluctuations in foreign currency exchange rates.

Interest Rate Exposure

Our cash and cash equivalents and restricted cash consist principally of money market securities that are short-term in nature. At March 31, 2023, our aggregate short-term and long-term investments were $780 million, consisting mostly of highly rated corporate debt securities and municipal securities. At March 31, 2023, we had $9.2 million amount of securities in an unrealized loss position. A hypothetical 100 basis point change in interest rates would result in an approximate $6.6 million change in interest income earned during the three months ended March 31, 2023.

On February 1, 2022, in connection with the completion of the sale of its semiconductor automation business, we used $49.7 million of the cash proceeds from the sale of the semiconductor automation business to extinguish the total remaining outstanding balance of our former term loan. We also closed our revolving credit facility of which had no borrowings. The term loan had a variable interest rate which subjected us to interest rate risk. Our primary interest rate risk exposure resulted from changes in the short-term LIBOR rate, the federal funds effective rate and the prime rate.

55

Table of Contents

Currency Rate Exposure

We have transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carrying foreign exchange risk are in Germany, the United Kingdom, Luxembourg, and China. Sales in currencies other than the U.S. dollar were approximately 24% and 37% of our total sales, respectively, during the six months ended March 31, 2023 and 2022. These sales were made primarily by our foreign subsidiaries, which have cost structures that substantially align with the currency of sale.

In the normal course of our business, we have liquid assets denominated in non-functional currencies which include cash, short-term advances between our legal entities and accounts receivable which are subject to foreign currency exposure. Such balances were approximately $114.5 million and $102.8 million, respectively, at March 31, 2023 and September 30, 2022, and primarily relate to the Euro, British Pound, and the Chinese yuan. We mitigate the impact of potential currency translation losses on these short-term intercompany advances by the timely settlement of each transaction, generally within 30 days. We also utilize forward contracts to mitigate our exposures to currency movement. We incurred foreign currency gains of $0.9 million and $1.1 million during the six months ended March 31, 2023 and 2022, respectively, which related to the currency fluctuation on these balances between the time the transaction occurred and the ultimate settlement of the transaction. A hypothetical 10% change in foreign exchange rates at March 31, 2023 and 2022 would result in an approximate change of $3.2 million and less than $0.2 million, respectively, in our net income during the six months ended March 31, 2023 and 2022.

​

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, and pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act, the Company’s management, including our chief executive officer and chief financial officer, has concluded that our disclosure controls and procedures are effective.

In October 2022, we acquired B Medical Systems S.á r.l. and its subsidiaries (“B Medical”). We are in the process of evaluating the existing controls and procedures of B Medical and integrating B Medical into our internal control over financial reporting. In accordance with SEC Staff guidance permitting a company to exclude an acquired business from management’s assessment of the effectiveness of internal control over financial reporting for a period of one year following the date on which the acquisition is completed, we have excluded B Medical’s internal control over financial reporting from our assessment of disclosure controls and procedures as of the end of the period covered by this report. The total assets and total revenues of B Medical represent 2% and 18%, respectively, of the related consolidated financial statement amounts as of and for the six months ended March 31, 2023. Refer to Note 5, “Business Combinations – Acquisition Completed in Fiscal Year 2023” in the Notes to the unaudited consolidated financial statements included in Item 1 “Consolidated Financial Statements” of this Quarterly Report on Form 10-Q.

Change in Internal Controls. Except for the acquisition of B Medical noted above, there were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

​

56

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. We cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this Quarterly Report on Form 10-Q, we believe that none of these claims will have a material adverse effect on our consolidated financial condition or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that our assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time to time, have a material adverse effect on our consolidated financial condition or results of operations in particular quarterly or annual periods.

​

Item 1A. Risk Factors

You should carefully review and consider the information regarding certain factors that could materially affect our business, consolidated financial condition or results of operations set forth under Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K. There have been no material changes from the risk factors disclosed in our 2022 Annual Report on Form 10-K. We may disclose changes to risk factors or additional factors from time to time in our future filings with the SEC.

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer’s Purchases of Equity Securities

​ | ​ | ​ | ​ | ​ | ​ | ​
Period of Repurchase | Total Number of Shares Purchased (#) (1) | ​ | Average Price Paid Per Share ($) (1) | Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs (#) (1) | ​ | Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under Our (in millions) ($) (1) (2) ​
January 1 – 31, 2023 | - | $ | - | - | $ | 1,000
February 1 – 30, 2023 | - | ​ | - | - | - | 1,000
March 1 – 31, 2023 | - | ​ | - | - | ​ | 1,000
Total | - | $ | - | - | $ | 1,000

​

​

| (1) | On November 4, 2022, our Board of Directors approved a new share repurchase authorization for the repurchase of up to $1.5 billion of our common stock, or the 2022 Repurchase Authorization, and terminated our previously authorized $50 million share repurchase authorization. On November 23, 2022, as part of the 2022 Repurchase Authorization, we entered into an accelerated share repurchase agreement, or the ASR Agreement, with JPMorgan Chase Bank, National Association, or the Dealer, for the repurchase of up to $500 million of our common stock. Approximately 6.1 million initial shares of common stock were received by us and retired in connection with entering into the ASR Agreement in November 2023. No shares were delivered to us under the ASR Agreement during the quarter ended March 31, 2023. On April 3, 2023, the transactions under the ASR Agreement terminated and, on April 5, 2023, we received final settlement of an additional 4 million shares of common stock for a total of approximately 10 million shares of common stock repurchased under the ASR Agreement. See Note 11, “Stockholders’ Equity” and Note 18, “Subsequent Event” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q for additional information about the ASR Agreement.

57

Table of Contents

| (2) | Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which we expect to repurchase up to an additional $500 million shares of our common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

Item 6. Exhibits

The following exhibits are included herein:

​ ​ | ​ | ​
Exhibit No. |  | Description
​ | ​ | ​
31.01 | ​ | Certification of the Company’s Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
31.02 | ​ | Certification of the Company’s Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
32 | ​ | Certification of the Company’s Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
101 | ​ | The following material from the Company’s Quarterly Report on Form 10-Q, for the quarter ended March 31, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the unaudited Consolidated Balance Sheets; (ii) the unaudited Consolidated Statements of Operations; (iii) the unaudited Consolidated Statements of Comprehensive Income; (iv) the unaudited Consolidated Statements of Cash Flows; (v) the unaudited Consolidated Statements of Changes in Stockholders’ Equity; and (vi) the Notes to the unaudited Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because XBRL tags are embedded in the iXBRL document.
​ | ​ | ​
104 | ​ | Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101).

​

​

​

58

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​ | ​
​ | AZENTA, INC.
​ | ​
Date: May 10, 2023 | /s/ Lindon G. Robertson
​ | Lindon G. Robertson
​ | Executive Vice President and Chief Financial Officer
​ | (Principal Financial Officer)
​ | ​
Date: May 10, 2023 | /s/ Vandana Sriram
​ | Vandana Sriram
​ | Senior Vice President-Global Finance
​ | (Principal Accounting Officer)

​

​

59